

Project Approved Form	
1. Project identification	
Project Change n°	1
Date of approval by the Monitoring Committee	2017-05-05
1.0 Code number	EAPA_151/2016
1.1 Acronym	
1.1.1 Acronym	BLUEHUMAN
1.1.2 Project email address	
1.2 Programme Priority	
1.2.1 Programme priority	1. Stimulating innovation and competitiveness
1.2.2 Programme specific objective	1.2. Strengthening the transfer of innovation results to facilitate the emergence of new products, services and processes
1.2.3 Fields of intervention	SME business development (500) , Productive investment in SMEs (500) , Advanced support services for SMEs and groups of SMEs (600) , Research and innovation processes in SMEs (2800) , Research and innovation activities in public research centres (2800) , Technology transfer and university-enterprise cooperation (2800)
1.3 Total budget	
1.3.1 ERDF	1,892,901.00€
1.3.2 Partners contribution	630,967.00€
1.3.3 Eligibles costs	2,523,868.00€
1.3.4 Total costs	2,523,868.00€
1.4 Title	<p>EN: BLUE biotechnology as a road for innovation on HUMAN's health aiming smart growth in Atlantic Area</p> <p>ES: Biotecnología AZUL como innovación en la salud HUMANA para el crecimiento inteligente en Europa</p> <p>FR: Biotechnologie BLEUE: voie innovante en santé humaine pour une croissance intelligente dans l'E Atl</p> <p>PT: Biotecnologia azul como inovação em saúde humana como crescimento inteligente no Espaço Atlântico</p>
1.5 Project duration	
1.5.1 Start date	2018-01-01
1.5.2 End date	2020-12-31
1.5.3 Project duration in months	36
1.6 Project background	
1.6.0 Project has started	0

Project Approved Form	
1.6.1 Project based on previous AA projects?	1
1.6.2 If the project is based on previous AA projects, please detail how it builds on from results of such previous projects	<p>EN: BLUEHUMAN is based on 3 previous AA projects: BIOTECMAR, VALBIOMAR and MARMED in which some partners worked but none of the companies. The intention is to remark the importance of the experience in those projects and results through a project where the companies ensure the use of that expertise.</p> <p>ES: FR: PT:</p>
1.6.3 Project based on other programmes/policies results?	1
1.6.4 If the project is based on other programmes/policies results, please detail	<p>EN: The BLUEHUMAN partners have participated in projects regarding marine valorization such as: -POCTEC: PROTEUS/SP1.P151/03, 0330_IBEROMARE_1_P, 0687_NOVOMAR_1_P. -LIFE: iSEAS- LIFE13 ENV/ES/000131, BE-FAIR- LIFE05 ENV/ES/000267.</p> <p>ES: FR: PT:</p>
1.6.5 Have you applied for the same project for another EU funding programmes?	0
1.6.6 If yes, explain which programmes	<p>EN: ES: FR: PT:</p>
1.6.7 Have you ever been beneficiaries of the Atlantic Area Programme?	1
1.6.8 If yes, explain which projects	<p>EN: Apart from the Atlantic Area projects specified in 1.6.2, some partners have participated in other thematics in the framework of this Programme such as: ACRUNET – 2011-1/148; CRUSTASEA – COLL-CT-2006-030421; ARCOPOL 2008-1/061; ARCOPOL+2011-1/150; ARCOPOL PLATFORM 2013-1/252; GEPETO 2011-1/159...</p> <p>ES: FR: PT:</p>
1.7 MONITORING COMMITTEE STAGE 2 recommendations if any	<p>EN: The sections 4.1 (influence on AA), 4.8.1 and 4.8.3 (quantified benefits), 1.6.2. (avoid duplication), 4.7.1 and 4.7.4 (risk assessment) were revised to account for the indicated recommendations from the Monitoring Committee. Moreover, two additional modifications were made, as following. From one side, the consortium requests a modification of the starting date of the project, delaying it to 1st of January 2018. About 3 quarters of the consortium members, representing as well about 3 quarters of the budget, are public institutions that required the signed contract to be able to start the internal</p>

Project Approved Form

procedures for the financial execution of the project. In this regard, given that we are still proceeding with amendments to the project proposal, which will be evaluated by the Programme Authorities, we believe that by moving the project to January 2018 (and concluding at December 2020) will maximize the capacity of the consortium to successfully execute technically and financially the project. Additionally, CIIMAR team is requesting the change of the host institution from CIIMAR to FCUP, due to administrative and organizational restrictions that the former institution is facing for the execution of the project. As the team members of this partner have double affiliation, FCUP will become the project partner and will give institutional support to the technical team, with all the tasks foreseen in the description of the work being fully guarantee.

ES:

FR:

PT:

1.8 MONITORING COMMITTEE STAGE
2 Conditions for approval if any

EN:

Not applicable.

ES:

FR:

PT:

1.9 Project documents

1.9.1 Subsidy contract

1.9.1.1 Contract date

1.9.1.2 Contract file

1.9.2 Partnership agreement

1.9.2.1 Partnership agreement date

1.9.2.2 Partnership agreement file

1.9.3 Project start declaration

1.9.3.1 Project start declaration date

2017-09-20

1.9.3.2 Project start declaration file

Anx_21736/2017

1.9.4 Proof of Solvability To be provided only by the lead partner (in case of public authority is enough a document justifying the legal status of the entity)

1.9.4.1 Date

2013-01-13

1.9.4.2 Solvability documents

Anx_23475/2017

1.9.5 Written agreement with Countries outside the Interreg AA eligible area

1.9.5.1 Document date

1.9.5.2 Agreement

2. Project partnership

Partner number	Entity	Position	Country	Region	New partner	Suspended
1	Universidade do Minho	1	Portugal	Norte	No	No

Project Approved Form

Partner number	Entity	Position	Country	Region	New partner	Suspended
2	Centro Tecnológico del Mar – Fundación CETMAR	2	Spain	Galicia	No	No
3	Centro Interdisciplinar de Investigação Marinha e Ambiental	2	Portugal	Norte	No	Yes
4	Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas	2	Spain	Galicia	No	No
5	Université de Bretagne Occidentale	2	France	Bretagne	No	No
6	SAS YSLAB	2	France	Bretagne	No	No
7	Universidade do Algarve	2	Portugal	Algarve	No	No
8	Universidad de Vigo	2	Spain	Galicia	No	No
9	Royal College of Surgeons in Ireland	2	Ireland	Southern and Eastern	No	No
10	Universidade da Madeira	2	Portugal	Madeira	No	No
11	JELLAGEN PTY LTD	2	United Kingdom	East Walles	No	No
12	SURGACOLL Technologies Limited	2	Ireland	Southern and Eastern	No	No
13	Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal	2	Spain	Galicia	No	No
14	Axencia Galega de Innovación	3	Spain	Galicia	No	No
15	Agência Nacional de Inovação	3	Portugal	Norte	No	No
16	Agencia Estatal de Investigación (MINECO)	3	Spain	Comunidad de Madrid	No	No
17	FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO	2	Portugal	Norte	Yes	No

2.0 Partner number

1

Project Approved Form	
2.1 Position in the partnership	Lead partner
2.2 Entity	
2.2.1 Organization acronym when applicable	UMINHO
2.2.2 Organization name	Universidade do Minho
2.2.3 Organization name in English	University of Minho
2.2.4 Department	3B's Research Group
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Public body
2.2.7 Tax ID	502011378
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	Anx_26037/2017
2.2.8 Website	www.uminho.pt; www.3bs.uminho.pt
2.2.9 Size of the organization (employees)	2330
2.3 Location	
2.3.1 Country	Portugal
2.3.2 Sub-Region (NUTS3)	Norte
2.3.3 City	Braga
2.3.4 Address	3B's Research Group - Universidade do Minho, Avepark – Parque de Ciência e Tecnologia, Zona Industrial da Gandra
2.4 Partner profile	
2.4.1 Partner skills	EN: 3B's-UMinho has large and strong expertise in biomaterials, tissue engineering, regenerative medicine, stem cells and nanomedicine. Particularly, development of marine biomaterials envisaging medical devices and tissue engineering scaffolds. It's also the coordinator of the research network CVMar. ES: FR: PT:
2.4.2 Transnational experience	EN: Coordination of several projects of european territorial cooperation under the theme of valorization of marine resources and by-products, namely projects PROTEUS (INTERREG IIIA), IBEROMARE (POCTEP), MARMED (Atlantic Area) and NOVOMAR (POCTEP). Besides, several FP7 and H2020 projects. ES: FR: PT:

Project Approved Form	
2.4.3 Role in the project	<p>EN: Coordinator of the project, being thus the leader of WP1. Member of the Research Consortium leading with experimental work, namely valorization of marine origin by-products as biomaterials for biomedical application. Development of science, technology and products towards innovation.</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: UMINHO will be the project coordinator, being thus responsible to implement the management strategy and to coordinate the tasks of project monitoring and evaluation (WP1). It will be as well deeply enrolled in communication activities for other scientists and companies, the general society and authorities (WP2). Besides, interactions with the mentioned stakeholders will be also explored aiming the capitalization of project results (WP3). Activities on the formulation of biomaterials using marine origin compounds, their characterization and evaluation of performance as potential systems for further research on regenerative medicine (WP4) or as potential medical devices (WP5) will be performed. This experimental work will build onto the results from previous projects, now with active participation of companies, towards the overcoming of current technical bottlenecks or the proposition of new routes of innovation and respective industrial processes.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Rui Luís Gonçalves dos Reis
2.5.2 Email	rgreis@dep.uminho.pt
2.5.3 Phone	+351253510900
2.5.4 Address	3B's Research Group - University of Minho, Avepark - Parque de Ciência e Tecnologia
2.5.5 Post code	4805-017
2.5.6 City	Barco – Guimarães
2.5.7 Country	Portugal
2.6 Legal representative	
2.6.1 Name	Rui Luís Gonçalves dos Reis – Vice-Reitor para a Investigação
2.6.2 Email	sec-rlreis@reitoria.uminho.pt
2.6.3 Phone	+351 253601050
2.6.4 Address	Largo do Paço
2.6.5 Post code	4704-553
2.6.6 City	Braga
2.6.7 Country	Portugal
2.6.8 Date of entering into functions	2013-11-18

Project Approved Form	
2.6.9 Probative document of the Legal representative	Anx_21741/2017
2.7 Bank account	
2.7.1 IBAN	PT50 0035 0171 00167322630 15
2.7.2 SWIFT	CGDIPTPL
2.7.3 Bank	CAIXA GERAL DE DEPÓSITOS
2.7.4 Bank Account Owner	Universidade do Minho
2.7.5 Bank Account Country	Portugal
2.7.6 DTCC Code	Braga
2.7.7 Bank Statement	Anx_21744/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-20
2.8.2 Co-financing declaration	Anx_21742/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-20
2.9.2 State Aid Declaration	Anx_21743/2017
2.0 Partner number	2
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	CETMAR
2.2.2 Organization name	Centro Tecnológico del Mar – Fundación CETMAR
2.2.3 Organization name in English	Technological Center of the Sea - CETMAR Foundation
2.2.4 Department	Fishery Products Technology
2.2.5 Type of organization	Research and innovation organisations
2.2.6 Legal status	Public body
2.2.7 Tax ID	G36885853
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	<p>EN: CETMAR is subject to the General VAT Regime of the Spanish Tax System, and VAT recovery is made through quarterly declarations to the Spanish Tax Agency, so that CETMAR does not justify the VAT in its project expenses. The amount of VAT that can be recovered will depend on the volume of VAT issued.</p> <p>ES: FR: PT:</p>
2.2.7.3 VAT statement	Anx_21844/2017
2.2.8 Website	http://www.cetmar.org/

Project Approved Form	
2.2.9 Size of the organization (employees)	44
2.3 Location	
2.3.1 Country	Spain
2.3.2 Sub-Region (NUTS3)	Galicia
2.3.3 City	Vigo
2.3.4 Address	c/ Eduardo Cabello, s/n
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: CETMAR has demonstrated ability in the coordination, harmonization, communication and networking of regional, national and European R + D + I initiatives, promoting cooperation, training activities, technological development and innovation between key actors of different nature related to the sea.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.2 Transnational experience	<p>EN: CETMAR has participated in two Atlantic Area Interreg projects (BIOTECMAR and MARMED), and two LIFE projects (BE-FAIR and iSEAS). From an integrative and transnational approach, these projects deals with recycling, reuse, management and valorization of marine resources for different applications.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.3 Role in the project	<p>EN: CETMAR will participate as a support office to the project leader, UMinho, in the WP 1 Coordination, and to the WP 3 leader, GNP-AECT, about Capitalization. Moreover, CETMAR will act as the WP 2 leader about Communication.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: In the WP1 CETMAR will give a special support to the leader. CETMAR will lead the WP2 about Communication as well as all the actions, making a continuous effort to involve all the partners who will play an important role. A special emphasis will be put on keeping the internal communication in the partnership as the basis to succeed in the external communication. It will develop and keep updated the Communication Plan and the Website and social media; it will organize two seminars, it will monitor the making of the project's video; it will design and edit the flyer, the newsletter, the poster and the brochures. In the WP3 CETMAR will collaborate in the Capitalization Plan so as to avoid overlaps with the WP2 (A3.1); it will contact the required national authorities (A3.2) and the companies and potential partners (A3.3).</p>

Project Approved Form	
	CETMAR will also give a technical support to the strategy of creation of the Roadmap (A3.4) and the capitalization events (A3.5). ES: FR: PT:
2.5 Contact person	
2.5.1 Name	Julio Maroto Leal
2.5.2 Email	jmaroto@cetmar.org
2.5.3 Phone	+34986247047
2.5.4 Address	c/ Eduardo Cabello, s/n
2.5.5 Post code	36208
2.5.6 City	Vigo
2.5.7 Country	Spain
2.6 Legal representative	
2.6.1 Name	Paloma Rueda Crespo
2.6.2 Email	prueda@cetmar.org
2.6.3 Phone	+34986247047
2.6.4 Address	c/ Eduardo Cabello, s/n
2.6.5 Post code	36208
2.6.6 City	Vigo
2.6.7 Country	Spain
2.6.8 Date of entering into functions	2009-06-26
2.6.9 Probative document of the Legal representative	Anx_21843/2017
2.7 Bank account	
2.7.1 IBAN	ES9820800572553040000459
2.7.2 SWIFT	CAGLESMMXXX
2.7.3 Bank	ABANCA CORPORACIÓN BANCARIA, S.A.
2.7.4 Bank Account Owner	CENTRO TECNOLÓGICO DEL MAR - FUNDACIÓN CETMAR
2.7.5 Bank Account Country	Spain
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21847/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-14
2.8.2 Co-financing declaration	Anx_21845/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-20
2.9.2 State Aid Declaration	Anx_21846/2017

Project Approved Form	
2.0 Partner number	3
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	CIIMAR
2.2.2 Organization name	Centro Interdisciplinar de Investigação Marinha e Ambiental
2.2.3 Organization name in English	Interdisciplinary Centre of Marine and Environmental Research
2.2.4 Department	Blue Biotechnology and Ecotoxicology Research Group
2.2.5 Type of organization	Research and innovation organisations
2.2.6 Legal status	Not-for-profit private organization
2.2.7 Tax ID	PT508792657
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	Anx_23511/2017
2.2.8 Website	www.ciimar.up.pt
2.2.9 Size of the organization (employees)	430
2.3 Location	
2.3.1 Country	Portugal
2.3.2 Sub-Region (NUTS3)	Norte
2.3.3 City	Matosinhos
2.3.4 Address	Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos s/n
2.4 Partner profile	
2.4.1 Partner skills	EN: CIIMAR's highly multidisciplinary team is involved in research in the Blue Biotechnology area. The team is capable of cultivating microorganisms in large scale from its rich culture collection, extract their added value components and test their potential in a battery of biological activity assays. ES: FR: PT:
2.4.2 Transnational experience	EN: CIIMAR has been involved in projects funded by transnational cooperation programmes in the framework of the "European Territorial Cooperation" objective (ARCOPOL, ARCOPOLplus, ATLANTOX, SHAREBIOTECH, PHARMATLANTIC, MARNET) and by the Operational Programme for Cross-border Cooperation Spain-Portugal. ES:

Project Approved Form	
	FR: PT:
2.4.3 Role in the project	EN: CIIMAR will furnish organic fractions obtained from cyanobacterial biomass to other partners, to be tested for different biological activities. In addition, CIIMAR will test extracts and fractions generated by the consortium in its in-house anti-obesity assays. ES: FR: PT:
2.4.4 Describe the activities that your organisation is going to implement in the project	EN: CIIMAR will involve in the three mandatory WP (1-3), and particularly in WP 6: Marine Ingredients for cosmetics, wellbeing and healthcare products. At this respect, CIIMAR will use strains from its culture collection of cyanobacteria (LEGEcc, lege.ciimar.up.pt), obtain organic extracts from their biomass and fractionate these extracts into fractions of different polarity. These fractions (315 projected) will be furnished to the consortium to be screened for different biological activities relevant for human health. Taking advantage of CIIMAR's biotechnology pipeline, it will also carry out the screening of extracts and fractions generated in the Project in a series of anti-obesity assays. CIIMAR will also participate in the characterization of enriched fractions and characterization of their main components. ES: FR: PT:
2.5 Contact person	
2.5.1 Name	Pedro Nuno da Costa Leão
2.5.2 Email	pedronunoleao@gmail.com
2.5.3 Phone	+351223401814
2.5.4 Address	Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos s/n
2.5.5 Post code	4450-208
2.5.6 City	Matosinhos
2.5.7 Country	Portugal
2.6 Legal representative	
2.6.1 Name	Vitor Vasconcelos
2.6.2 Email	vmvascon@fc.up.pt
2.6.3 Phone	+351223401800
2.6.4 Address	Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos s/n
2.6.5 Post code	4450-208
2.6.6 City	Matosinhos
2.6.7 Country	Portugal

Project Approved Form	
2.6.8 Date of entering into functions	2017-10-10
2.6.9 Probative document of the Legal representative	Anx_23509/2017
2.7 Bank account	
2.7.1 IBAN	PT50003502050000568173096
2.7.2 SWIFT	CGDIPTPL
2.7.3 Bank	NOT APPLICABLE
2.7.4 Bank Account Owner	NOT APPLICABLE
2.7.5 Bank Account Country	Portugal
2.7.6 DTCC Code	Porto
2.7.7 Bank Statement	Anx_23510/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-10-10
2.8.2 Co-financing declaration	Anx_23512/2017
2.9 State aid declaration	
2.9.1 Date	2017-10-10
2.9.2 State Aid Declaration	Anx_23513/2017
2.0 Partner number	4
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	IIM-CSIC
2.2.2 Organization name	Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Cientificas
2.2.3 Organization name in English	Marine Research Institute - Spanish National Research Council
2.2.4 Department	Group of Food Biochemistry (BA) and Group of Recycling and Valorization of Waste Materials (REVAL)
2.2.5 Type of organization	Research and innovation organisations
2.2.6 Legal status	Public body
2.2.7 Tax ID	Q2818002D
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: Annually calculated ES: FR: PT:
2.2.7.3 VAT statement	Anx_21860/2017
2.2.8 Website	www.iim.csic.es

Project Approved Form	
2.2.9 Size of the organization (employees)	15000
2.3 Location	
2.3.1 Country	Spain
2.3.2 Sub-Region (NUTS3)	Galicia
2.3.3 City	Vigo
2.3.4 Address	c/ Eduardo Cabello 6
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: IIM-CSIC has been involved for many years in the development of procedures at lab and pilot plant scale for the valorization of different fish discards and by-products (skin, bone, viscera, exoesqueletons, etc.) to obtain several products for biomedical uses (collagen, chitosan, chondroitin, etc.)</p> <p>ES: FR: PT:</p>
2.4.2 Transnational experience	<p>EN: IIM-CSIC has coordinated two LIFE projects (BE-FAIR and FAROS) and is coordinating another one (iSEAS) dealing with the quantification, management and valorization of these materials. Also, it has participated in 2 INTERREG Atlantic Area projects (BIOTECMAR and MARMED) dealing with similar thematic.</p> <p>ES: FR: PT:</p>
2.4.3 Role in the project	<p>EN: IIM-CSIC will be involved in the execution, in collaboration with other partners, of the actions A1.1, A1.2, A1.3 from WP1, A2.1, A2.2, A2.3, A2.4, A2.5, from WP2, A3.2, A3.3, A3.5 from WP3, A4.1, A4.2, A4.4, A4.5 from WP4, A5.1, A5.4 from WP5 and A6.3 from WP6.</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: Initially, the main contribution will be the sustainable and tailored production of marine origin compounds (glycosaminoglycan, collagen and derivatives, etc.) with different physicochemical features (molecular weights, etc.) useful for the several applications described in the proposal. Subsequently, IIM-CSIC will work, together with other partners, in the chemical modification of collagen (crosslinking), development of hydrogels of collagen from cartilaginous fish for cartilage therapies, formulation of blends based on collagen and chondroitin sulfate for wound healing (wound protection) and stem cells encapsulation, development of scaffolds defined by combinations of shark collagen and bioapatites for bone regeneration, and production of nanoparticles to deliver hyaluronic acid and collagen hydrolysates useful for cosmetic applications. We are also involved in different tasks of project management and coordination, communication and dissemination, and capitalization.</p>

Project Approved Form	
	ES: FR: PT:
2.5 Contact person	
2.5.1 Name	Ricardo I. Pérez-Martín – Xosé A. Vázquez Álvarez
2.5.2 Email	ricardo@iim.csic.es
2.5.3 Phone	+34986231930
2.5.4 Address	c/ Eduardo Cabello 6
2.5.5 Post code	36208
2.5.6 City	Vigo
2.5.7 Country	Spain
2.6 Legal representative	
2.6.1 Name	Cristina de la Puente González
2.6.2 Email	vicyt@csic.es
2.6.3 Phone	+34 915681568
2.6.4 Address	C/ Serrano, 117
2.6.5 Post code	28006
2.6.6 City	Madrid
2.6.7 Country	Spain
2.6.8 Date of entering into functions	2016-04-14
2.6.9 Probative document of the Legal representative	Anx_21858/2017
2.7 Bank account	
2.7.1 IBAN	ES0790000001200220000047
2.7.2 SWIFT	ESPBESMM
2.7.3 Bank	BANCO DE ESPAÑA
2.7.4 Bank Account Owner	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
2.7.5 Bank Account Country	Spain
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21856/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-19
2.8.2 Co-financing declaration	Anx_21861/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-20
2.9.2 State Aid Declaration	Anx_21852/2017

Project Approved Form	
2.0 Partner number	5
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	UBO
2.2.2 Organization name	Université de Bretagne Occidentale
2.2.3 Organization name in English	Western Bretagne University
2.2.4 Department	LEMAR (Laboratoire des sciences de l'environnement marin) UMR 6539 UBO CNRS IFREMER IRD
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Public body
2.2.7 Tax ID	FR 68192903466
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: UBO recovers 100% of VAT on research activities ES: FR: PT:
2.2.7.3 VAT statement	Anx_21853/2017
2.2.8 Website	www.univ-brest.fr
2.2.9 Size of the organization (employees)	2258
2.3 Location	
2.3.1 Country	France
2.3.2 Sub-Region (NUTS3)	Bretagne
2.3.3 City	Brest
2.3.4 Address	LEMAR – IUEM, rue Dumont D'Urville – Technopôle Brest Iroise
2.4 Partner profile	
2.4.1 Partner skills	EN: Knowledge on: The diversity of marine macrophytes; Biochemistry of proteins and enzyme engineering; Extraction, purification, structural elucidation and quantification of bioactive compounds from marine macrophytes; and, Screening for antibacterial activities and inhibition of biofilm formation. ES: FR: PT:
2.4.2 Transnational experience	EN: As a lead partner: INTERREG-IVB-Atlantic-Area (BIOTECMAR). Partners in several EU projects: INTERREG IV B Atlantic-Area (MARMED and GIMS); FP7 KBBE (BIVALIFE and MACUMBA); ERA-NET SEAS-ERA (INVASIVE and LEAF); FP6 (SEAFOODplus and CHEM-FREE); COST (ENBA); and, ERA-NET-BIOME POMARE 2012-2015.

Project Approved Form	
	ES: FR: PT:
2.4.3 Role in the project	EN: Interaction with industrial and academic partners for preparing marine collagens scaffolds with compounds from macrophytes species, and isolation of multifunctional molecules extracted from macrophytes. Formulation and promotion of fish collagen and macrophytes bioactive compounds in biomaterials. ES: FR: PT:
2.4.4 Describe the activities that your organisation is going to implement in the project	EN: Participation in WP1; WP2 (2.1, 2.2, 2.3, 2.4, 2.5); WP3 (3.1, 3.3, 3.4, 3.5); WP4 (4.2); WP6 (6.1, 6.2, 6.3, 6.4). -Optimization of cross-linking reactions assisted by enzymes of collagen type I from salmon in order to improve its mechanical and structural properties. 1 Pilot action A4.2. -Preparation of fractions enriched in polyphenols from algae and halophytes using green innovative techniques in order to supply active molecules to Blue Human partners: Structural, chemical and biological characterization of a series of polyphenols. 1 Pilot action A6.1: 5 isolated compounds for assessment of pro-mineralogenic and osteogenic activities. -Preparation of new bioactive molecule from marine sources able to inhibit bacterial growth and biofilm formation. 1 pilot action A6.2: 2 extracts exhibiting antibacterial and/or anti-biofilm activities. -Publications in scientific journals. ES: FR: PT:
2.5 Contact person	
2.5.1 Name	Fabienne Guerard
2.5.2 Email	fabienne.guerard@univ-brest.fr
2.5.3 Phone	+33298498798
2.5.4 Address	LEMAR – IUEM, rue Dumont D'Urville – Technopôle Brest Iroise
2.5.5 Post code	29280
2.5.6 City	Plouzané
2.5.7 Country	France
2.6 Legal representative	
2.6.1 Name	Matthieu GALLOU
2.6.2 Email	president@univ-brest.fr
2.6.3 Phone	+33298016003
2.6.4 Address	3 rue des Archives – CS 93837
2.6.5 Post code	292388
2.6.6 City	Brest
2.6.7 Country	France

Project Approved Form	
2.6.8 Date of entering into functions	2016-03-29
2.6.9 Probative document of the Legal representative	Anx_21855/2017
2.7 Bank account	
2.7.1 IBAN	FR7610071290000000100279091
2.7.2 SWIFT	TRPUFRP1
2.7.3 Bank	DIRECTION DEPARTEMENTALE DES FINANCES PUBLIQUES DU FINISTERE
2.7.4 Bank Account Owner	AGENT COMPTABLE DE L'UBO
2.7.5 Bank Account Country	France
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21857/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-14
2.8.2 Co-financing declaration	Anx_21854/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-19
2.9.2 State Aid Declaration	Anx_21859/2017
2.0 Partner number	6
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	YSLAB
2.2.2 Organization name	SAS YSLAB
2.2.3 Organization name in English	YSLAB
2.2.4 Department	Research and Development department
2.2.5 Type of organization	Small and medium enterprises
2.2.6 Legal status	Profit-making private organization
2.2.7 Tax ID	RCS 433 203 593
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: VAT number FR38 433203593 ES: FR: PT:
2.2.7.3 VAT statement	Anx_21865/2017
2.2.8 Website	www.yslab.fr

Project Approved Form	
2.2.9 Size of the organization (employees)	10
2.3 Location	
2.3.1 Country	France
2.3.2 Sub-Region (NUTS3)	Bretagne
2.3.3 City	Quimper
2.3.4 Address	Le Forum, 2 rue Felix Le Dantec
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: Development of health and well-being products (medical devices, cosmetics) from marine ingredients. Safety and biological activity evaluation of marine ingredient and finished product.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.2 Transnational experience	<p>EN: Products sale in the international market (main customers in Russia, North America, latin America).</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.3 Role in the project	<p>EN: WP1: collaboration with all partners; WP2 (2.1, 2.2, 2.3, 2.5): collaboration with all partners; WP3 (3.3, 3.5): collaboration with all partners; WP4 (4.2): collaboration with UBO, IIM-CSIC; WP6 (6.1, 6.2, 6.3, 6.4): collaboration with UALG, CIIMAR, IIM-CSIC and UBO.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: WP1: Participation to 5 consortia meeting. Co-organization of the French meeting. Making re-ports for each audit. Participation to all exchange needed for the good progress of the project. WP2: Transmission of data and making documents for Communication. Participation to 1 CETMAR's seminar. WP3: Collection and transmission of data (3.3). Participation to final seminar. WP4: 4.2 Supplying of collagen from salmon skin for crosslinking. At least two different batch-es. Making all the analysis on this collagen to guaranty native structure and microbiological con-formity. WP5: If needed by some partners, salmon collagen can be supply. WP6: For activities 1 to 4: Participation to toxicological evaluation (regarding ISO 10993) and some biological activities (anti oxidative activity, impact on inflammation pathways, healing mechanisms...). Taking in count regulatory environment to ease access to market. Formulation of products (only for 6.2). Market studies. Study of patent opportunities.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>

Project Approved Form	
2.5 Contact person	
2.5.1 Name	Roxane Fagon
2.5.2 Email	roxane.fagon@yslab.fr
2.5.3 Phone	+33298533003
2.5.4 Address	Le Forum, 2 rue Felix Le Dantec
2.5.5 Post code	29000
2.5.6 City	Quimper
2.5.7 Country	France
2.6 Legal representative	
2.6.1 Name	Kerdiles Guillaume
2.6.2 Email	kerdilesg@hotmail.com
2.6.3 Phone	+33298533003
2.6.4 Address	Le Forum, 2 rue Felix Le Dantec
2.6.5 Post code	29000
2.6.6 City	Quimper
2.6.7 Country	France
2.6.8 Date of entering into functions	2016-09-05
2.6.9 Probative document of the Legal representative	Anx_21864/2017 Anx_26039/2017
2.7 Bank account	
2.7.1 IBAN	FR7615589297150495458514061
2.7.2 SWIFT	CMBRFR2BARK
2.7.3 Bank	CREDIT MUTUEL DE BRETAGNE
2.7.4 Bank Account Owner	YS LAB
2.7.5 Bank Account Country	France
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21862/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-19
2.8.2 Co-financing declaration	Anx_21866/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-19
2.9.2 State Aid Declaration	Anx_21867/2017
2.0 Partner number	7
2.1 Position in the partnership	Partner
2.2 Entity	

Project Approved Form	
2.2.1 Organization acronym when applicable	UALg
2.2.2 Organization name	Universidade do Algarve
2.2.3 Organization name in English	University of Algarve
2.2.4 Department	Department of Biomedical Sciences and Medicine
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Public body
2.2.7 Tax ID	PT505387271
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	Anx_21888/2017
2.2.8 Website	http://www.ualg.pt/pt
2.2.9 Size of the organization (employees)	1181
2.3 Location	
2.3.1 Country	Portugal
2.3.2 Sub-Region (NUTS3)	Algarve
2.3.3 City	Faro
2.3.4 Address	University of Algarve, Building 2, Campus de Gambelas
2.4 Partner profile	
2.4.1 Partner skills	EN: Knowledge on the mechanisms of skeletal development and homeostasis; Screening of extracts for osteogenic molecules with therapeutic and nutraceutical potential; Development of in vitro mineralization cell systems; Identification of gene and protein expression sites at single cell resolution, etc. ES: FR: PT:
2.4.2 Transnational experience	EN: Partner in several European projects: MARMED/2011-1/164 - Atlantic Area; I-One/ EU-FP7/280772; MECHANOCELL/ALW-GO-MG/10-0; ECOAQUA/ INTERREG IV A POCTEP/0251; FICEL /EU-FP6/GOCE-CT-2004-505403; PROMAR/SP5.P117/03; COST EuroSoftCalcNet/OC-2016-1-20781. ES: FR: PT:
2.4.3 Role in the project	EN: Extracts prepared from algae (UBO) and cyanobacteria (CIIMAR) will be tested by UALG for their capacity to stimulate in vitro mineralization and to

Project Approved Form	
	<p>promote bone formation in developing larvae and finectomized adult zebrafish. Industrial exploration of bioactive compounds will also be evaluated.</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: UALG will be involved in activities related to Project management and Coordination (WP1) through its participation in project meetings and reporting duties, to Communication and Dissemination (WP2) through the publication of project results in open-access peer-reviewed journals and production of material for the project website, videos and flyers, and to Capitalization (WP3) through presentation of project results in national and international meetings. UALG will be deeply involved in the technical activities related to Marine Ingredients for Cosmetics, Well-being and Healthcare Products (WP6) in particular action 6.1 Extracts from algae, cyanobacteria and halophytes with mineralogenic and osteogenic activities, where it will bring expertise and technical resources to assess the potential of marine extracts to promote bone formation/mineralization, towards the preparation of products with therapeutic, cosmetic and/or nutraceutical applications and transposition for industrial partners.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Leonor Cancela
2.5.2 Email	lcancela@ualg.pt
2.5.3 Phone	+351289800971
2.5.4 Address	University of Algarve, Building 2, Campus de Gambelas
2.5.5 Post code	8005-139
2.5.6 City	Faro
2.5.7 Country	Portugal
2.6 Legal representative	
2.6.1 Name	Pedro Ferre
2.6.2 Email	vrpferre@ualg.pt
2.6.3 Phone	+351 289800100
2.6.4 Address	University of Algarve, Campus da Penha
2.6.5 Post code	8005-139
2.6.6 City	Faro
2.6.7 Country	Portugal
2.6.8 Date of entering into functions	2014-09-01
2.6.9 Probative document of the Legal representative	Anx_21965/2017
2.7 Bank account	

Project Approved Form	
2.7.1 IBAN	PT50003502050000568173096
2.7.2 SWIFT	CGDIPTPL
2.7.3 Bank	CAIXA GERAL DE DEPOSITOS
2.7.4 Bank Account Owner	UNIVERSIDADE DO ALGARVE-PROJETOS COMUNITÁRIOS
2.7.5 Bank Account Country	Portugal
2.7.6 DTCC Code	Faro
2.7.7 Bank Statement	Anx_21886/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-25
2.8.2 Co-financing declaration	Anx_21884/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-25
2.9.2 State Aid Declaration	Anx_21885/2017
2.0 Partner number	8
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	UVIGO
2.2.2 Organization name	Universidad de Vigo
2.2.3 Organization name in English	University of Vigo
2.2.4 Department	Applied Physics Department
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Public body
2.2.7 Tax ID	ESQ8650002B
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: The University of Vigo recovers all the input VAT in research activities ES: FR: PT:
2.2.7.3 VAT statement	Anx_21894/2017
2.2.8 Website	https://uvigo.gal/
2.2.9 Size of the organization (employees)	2,134 employees
2.3 Location	
2.3.1 Country	Spain
2.3.2 Sub-Region (NUTS3)	Galicia
2.3.3 City	Vigo

Project Approved Form	
2.3.4 Address	EEl. Applied Physics Department Lagoas-Marcosende, s/n
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: UVigo has placed a considerable emphasis on R+D activities by way of numerous internal funded projects, as well as through its various services and research centres. This support has increased the scientific output. UVIGO appeared in Shanghai ranking in 2011 and 2012.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.2 Transnational experience	<p>EN: UVIGO participates every year in the Framework Programme and other initiatives of the EU; more than 45 European Projects has been developed since the year 2007 (some of them coordinated by UVIGO), with a return of more than 20 millions of euros (including, so far, more than 5 projects from H2020).</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.3 Role in the project	<p>EN: Main role will be the production and capitalization of Medical Devices. They will focus on the extraction of bioceramics from marine wastes in order to produce scaffolds for bone regeneration and bioceramic-based devices for bone tissue therapies.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: WP1 (Project management and coordination); WP2 in this work package UVigo is very keen to collaborate in the development and implementation of the communication strategy of the project, in the production and distribution of communication material, and in the publication of results in learned scientific journals, therefore UVigo will specifically participate in actions A2.1, A2.2, A2.3, and A2.5. Regarding WP3, UVigo is highly concerned about the need to capitalize the results of the project, therefore they will be very active in building a true collaborative innovation network and participate in Bluehuman capitalization events. More specifically UVIGO will participate in actions 3.1, 3.3, 3.4 and 3.5. UVigo will also participate in WP5 in which they will be very active in the production of scaffolds and calcium phosphates for bone regeneration (Action A5.1) and in the production of marine bioceramics for bone tissue therapies (Action A5.5).</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.5 Contact person	
2.5.1 Name	Juan María Pou Saracho
2.5.2 Email	jpou@uvigo.es
2.5.3 Phone	+34986812216

Project Approved Form	
2.5.4 Address	EEl. Applied Physics Department Lagoas-Marcosende, s/n.
2.5.5 Post code	36310
2.5.6 City	Vigo
2.5.7 Country	Spain
2.6 Legal representative	
2.6.1 Name	M ^a Asunción Longo González – Vice-rector of Research and Technology Transfer
2.6.2 Email	vicinv@uvigo.es
2.6.3 Phone	+34 986 813 597
2.6.4 Address	Anexo Edificio Xerencia e Servizos Centrais Campus Universitario de Vigo s/n
2.6.5 Post code	36310
2.6.6 City	Vigo
2.6.7 Country	Spain
2.6.8 Date of entering into functions	2014-04-28
2.6.9 Probative document of the Legal representative	Anx_21898/2017
2.7 Bank account	
2.7.1 IBAN	ES9102388103150660001660
2.7.2 SWIFT	POPUESMMXXX
2.7.3 Bank	BANCO POPULAR ESPAÑOL, SA
2.7.4 Bank Account Owner	UNIVERSIDADE DE VIGO
2.7.5 Bank Account Country	Spain
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21895/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-18
2.8.2 Co-financing declaration	Anx_21896/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-20
2.9.2 State Aid Declaration	Anx_21897/2017
2.0 Partner number	9
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	RCSI
2.2.2 Organization name	Royal College of Surgeons in Ireland
2.2.3 Organization name in English	Royal College of Surgeons in Ireland

Project Approved Form	
2.2.4 Department	Anatomy/ Tissue Engineering Research Group
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Not-for-profit private organization
2.2.7 Tax ID	EI2199803
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	Anx_21924/2017
2.2.8 Website	http://www.rcsi.ie/ http://www.rcsi.ie/tissueengineering
2.2.9 Size of the organization (employees)	1000
2.3 Location	
2.3.1 Country	Ireland
2.3.2 Sub-Region (NUTS3)	Southern and Eastern
2.3.3 City	Dublin
2.3.4 Address	Dept. Anatomy Royal College of Surgeons in Ireland 123 St. Stephen's Green
2.4 Partner profile	
2.4.1 Partner skills	EN: RCSI is a leading innovator in the development of advanced biomaterials for tissue engineering, with a major focus on functionalising these natural polymer scaffolds for use as delivery systems for biomolecules to enhance their therapeutic potential. ES: FR: PT:
2.4.2 Transnational experience	EN: Research in collaboration with numerous academic and industrial partners both nationally and internationally. Some examples of on-going projects with a transnational dimension include: Gene2Skin (H2020); LAF-GRAFT and VASCOLL (H2020, MSCA); AMBER (SFI). ES: FR: PT:
2.4.3 Role in the project	EN: The main role in BLUEHUMAN will be the production and capitalization of Marine Biomaterials and Medical Devices. Concretely, RCSI will focus on R +D manufacturing of marine biomaterials for tissue engineering, and of marine composites for functional medical devices. RCSI will have a role in WP 1-5. ES: FR: PT:

Project Approved Form	
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: For WP 1-3, RCSI will participate in: consortium meetings, preparation of dissemination materials and activities, and capitalizing the product outcomes. Its experience in collagen processing, crosslinking and characterisation will be utilised. In addition, the potential of using marine derived biomaterials will be investigated for developing next generation biomaterials to overcome the disease transmission risk associated with bovine derived tissue. Thus, for WP 4-5 RCSI will be involved in: Selection and optimization of potential combinations of marine-derived collagen and chondroitin to be used for the encapsulation of chondrocytes and stem cells; Development of collagen-based composite scaffolds functionalized with selected bioactives to be released in a controlled manner, using well-established protocols developed in the RCSI TERG and novel nanoparticle-mediated delivery systems; Development of trilayered scaffolds composed of marine-derived materials for osteoregeneration.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Fergal O'Brien
2.5.2 Email	fjobrien@rcsi.ie
2.5.3 Phone	+35314022149
2.5.4 Address	Dept. Anatomy Royal College of Surgeons in Ireland 123 St. Stephen's Green
2.5.5 Post code	Dublin 2
2.5.6 City	Dublin
2.5.7 Country	Ireland
2.6 Legal representative	
2.6.1 Name	Paola Della Porta
2.6.2 Email	pdellaporta@rcsi.ie
2.6.3 Phone	+3531 402 2393
2.6.4 Address	123 St. Stephen's Green
2.6.5 Post code	Dublin 2
2.6.6 City	Dublin
2.6.7 Country	Ireland
2.6.8 Date of entering into functions	2017-09-21
2.6.9 Probative document of the Legal representative	Anx_21922/2017 Anx_26035/2017 Anx_26038/2017
2.7 Bank account	
2.7.1 IBAN	IE83AIBK93115225685019
2.7.2 SWIFT	AIBKIE2D
2.7.3 Bank	AIB

Project Approved Form	
2.7.4 Bank Account Owner	ROYAL COLLEGE OF SURGEONS IN IRELAND
2.7.5 Bank Account Country	Ireland
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21923/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-21
2.8.2 Co-financing declaration	Anx_21920/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-21
2.9.2 State Aid Declaration	Anx_21921/2017
2.0 Partner number	10
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	UMA
2.2.2 Organization name	Universidade da Madeira
2.2.3 Organization name in English	University of Madeira (Madeira Chemistry Research Center)
2.2.4 Department	Centro de Química da Madeira (CQM)
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Public body
2.2.7 Tax ID	PT680041982
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: The university recovers 2% of VAT ES: FR: PT:
2.2.7.3 VAT statement	Anx_21932/2017
2.2.8 Website	http://cqm.uma.pt (CQM-Centro de Química da Madeira); http://www.uma.pt (Universidade da Madeira)
2.2.9 Size of the organization (employees)	410
2.3 Location	
2.3.1 Country	Portugal
2.3.2 Sub-Region (NUTS3)	Madeira
2.3.3 City	Funchal
2.3.4 Address	Centro de Química da Madeira, Universidade da Madeira, Campus da Penteadá

Project Approved Form	
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: The group has experience in nanochemistry and nanomaterials for biomedical applications (synthesis, characterization and biological evaluation).</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.2 Transnational experience	<p>EN: The group has collaborations abroad (especially with Spain, Finland and China). It has experience in INTERREG-MAC projects, Cytel projects and COST actions.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.3 Role in the project	<p>EN: The group will mainly participate in WP4. Marine Biomaterials for Tissue Engineering, A4.3. Functionalization of biomaterials with delivery devices for cartilage regeneration. The group will develop nanoscale vectors for the delivery of proteins/genes that direct cartilage formation within scaffolds</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: The group will participate in the following WPs: WP1: by participation in consortia meetings; WP2: by participation in communication and dissemination actions (particularly actions 2.1, 2.2, 2.3, 2.5); WP3: by participation in capitalization actions (namely actions 3.3 and 3.5); WP4: by participation in action 4.3; here, new nanoscale vectors for the delivery of biomolecules (proteins/genes) that direct cartilage formation within scaffolds will be developed; materials from marine origin will be explored in this process; the nanomaterials will be designed, synthesized, characterized by suitable physical-chemical techniques and their biological efficacy (transfection levels, proliferation/differentiation effects) will be evaluated using standard cell culture techniques before their use in 3D matrices through the collaboration with the other partners involved in WP4, action 4.3.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.5 Contact person	
2.5.1 Name	Helena Maria Pires Gaspar Tomás
2.5.2 Email	lenat@staff.uma.pt
2.5.3 Phone	+351291705110
2.5.4 Address	Centro de Química da Madeira, Universidade da Madeira, Campus da Penteadá
2.5.5 Post code	9000-390
2.5.6 City	Funchal

Project Approved Form	
2.5.7 Country	Portugal
2.6 Legal representative	
2.6.1 Name	José Manuel Cunha Leal Molarinho Carmo
2.6.2 Email	gabinete@reitoria.uma.pt
2.6.3 Phone	+ 351291209400
2.6.4 Address	Colégio dos Jesuítas, Rua dos Ferreiros
2.6.5 Post code	9000-082
2.6.6 City	Funchal
2.6.7 Country	Portugal
2.6.8 Date of entering into functions	2017-06-13
2.6.9 Probative document of the Legal representative	Anx_21931/2017
2.7 Bank account	
2.7.1 IBAN	PT50001800080147991302092
2.7.2 SWIFT	TOTAPTPL
2.7.3 Bank	SANTANDER TOTTA
2.7.4 Bank Account Owner	Universidade da Madeira
2.7.5 Bank Account Country	Portugal
2.7.6 DTCC Code	Funchal
2.7.7 Bank Statement	Anx_21933/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-19
2.8.2 Co-financing declaration	Anx_21930/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-19
2.9.2 State Aid Declaration	Anx_21929/2017
2.0 Partner number	11
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	JELLAGEN
2.2.2 Organization name	JELLAGEN PTY LTD
2.2.3 Organization name in English	JELLAGEN PTY LTD
2.2.4 Department	RDI
2.2.5 Type of organization	Small and medium enterprises
2.2.6 Legal status	Profit-making private organization
2.2.7 Tax ID	GB167685949

Project Approved Form	
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: VAT registered ES: FR: PT:
2.2.7.3 VAT statement	Anx_21942/2017
2.2.8 Website	www.jellagen.co.uk
2.2.9 Size of the organization (employees)	4 FTEs
2.3 Location	
2.3.1 Country	United Kingdom
2.3.2 Sub-Region (NUTS3)	East Walles
2.3.3 City	Cardiff
2.3.4 Address	Unit G5, Capital Business park
2.4 Partner profile	
2.4.1 Partner skills	EN: Considerable experience and expertise in fishing and processing jellyfish in a sustainable and efficient manner. Skills in collagen chemistry, handling and formulations with various additives. Skills in product realisation, marketing and commercialisation ES: FR: PT:
2.4.2 Transnational experience	EN: Jellagen has worked with partners on projects in France, and deals with a wide range of customers from around the world. Jellagen's CEO has had experience in several projects with worldwide partners. ES: FR: PT:
2.4.3 Role in the project	EN: Jellagen harvest jellyfish and supply jellyfish collagen into the Project. Jellagen will then work with Project partners and provide input into product creation and product development, along with carrying out formulation and support. ES: FR: PT:
2.4.4 Describe the activities that your organisation is going to implement in the project	EN: Jellagen will be involve in WP 1-3, assisting project leaders in the preparation of dissemination materials and activities, and will also carry out work to capitalise on product outcomes. This includes IP searches, patent applications and attendance at trade shows to gauge customer reception to products. It will also involve in WP 5 and 6, being the WP 6 leader. For both thematic WP, Jellagen will supply raw jellyfish collagen into the project. Jellagen will also work with collaborators in the partner to explore the feasibility/potential

Project Approved Form	
	<p>for creating medical devices, along with components from the consortium. This will include fishing activities to catch the raw material, processing of the material and extracting collagen as per Jellagen's proprietary in house capabilities. Jellagen will then process the collagen into a format for use (i.e. gel or sponge) and formulate with various products, crosslinkers and additives to give the material specific properties in Jellagen's laboratory.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Andrew Mearns Spragg
2.5.2 Email	andrew@jellagen.co.uk
2.5.3 Phone	+447585120853
2.5.4 Address	Unit G5, Capital Business park
2.5.5 Post code	CF32PX
2.5.6 City	Cardiff
2.5.7 Country	United Kingdom
2.6 Legal representative	
2.6.1 Name	Andrew Mearns Spragg
2.6.2 Email	andrew@jellagen.co.uk
2.6.3 Phone	+443333583299
2.6.4 Address	Unit G5, Capital Business Park
2.6.5 Post code	CF32PX
2.6.6 City	Cardiff
2.6.7 Country	United Kingdom
2.6.8 Date of entering into functions	2013-05-29
2.6.9 Probative document of the Legal representative	Anx_21944/2017
2.7 Bank account	
2.7.1 IBAN	GB36BARC20292343818802
2.7.2 SWIFT	BARCGB22
2.7.3 Bank	BARCLAYS BANK PLC
2.7.4 Bank Account Owner	JELLAGEN PTY LTD
2.7.5 Bank Account Country	United Kingdom
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21943/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-15
2.8.2 Co-financing declaration	Anx_21939/2017

Project Approved Form	
2.9 State aid declaration	
2.9.1 Date	2017-09-29
2.9.2 State Aid Declaration	Anx_21938/2017
2.0 Partner number	12
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	SURGACOLL
2.2.2 Organization name	SURGACOLL Technologies Limited
2.2.3 Organization name in English	SURGACOLL Technologies Limited
2.2.4 Department	RDI
2.2.5 Type of organization	Small and medium enterprises
2.2.6 Legal status	Profit-making private organization
2.2.7 Tax ID	IE 9768762Q
2.2.7.1 VAT recovery	1
2.2.7.2 If YES explain how?	EN: IE 9768762Q ES: FR: PT:
2.2.7.3 VAT statement	Anx_21940/2017
2.2.8 Website	www.surgacoll.com
2.2.9 Size of the organization (employees)	8
2.3 Location	
2.3.1 Country	Ireland
2.3.2 Sub-Region (NUTS3)	Southern and Eastern
2.3.3 City	Dublin
2.3.4 Address	SurgaColl Technologies Limited, Invent, Dublin City University
2.4 Partner profile	
2.4.1 Partner skills	EN: SurgaColl Technologies Ltd., a medical devices company, develops novel tissue regeneration products for the surgical treatment of disease of bone, cartilage, and other human tissue. The company also engages in the development, production, sales, and marketing of implantable medical devices. ES: FR: PT:
2.4.2 Transnational experience	EN:

Project Approved Form	
	<p>Surgacoll has worked with partners on projects in Ireland, and deals with a wide range of customers from around the world. Surgacoll's CEO has had experience in several projects with worldwide partners.</p> <p>ES: FR: PT:</p>
2.4.3 Role in the project	<p>EN: Contribution to the preparation of dissemination materials and activities as well as the capitalisation of product outcomes (WP 1-3). Research and Development manufacturing of a range of biomaterial composites based on marine-derived biomaterials (WP 4 and 5, being the leader in WP 5).</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: The activities implemented in WP 4 and 5 will be: Scaffolds made of shark collagen and shark calcium phosphates for bone regeneration – development and optimisation of manufacturing process to achieve stable shark-based biomaterial implants, with associated benchtop testing characterisation; Develop functional scaffolds, i.e., supplemented with bioactive compounds to be delivered in a sustained way – identified novel and relevant biomolecules in collaboration with the Project partners and utilise soak loading and novel biological incorporation techniques to achieve long term sustained local delivery of factors; Development of tri-layered biomaterials for osteochondral defects – assessment of compatibility of novel marine based biomaterials with osteochondral tissues once fabricated; and, Marine ceramics for bone tissue therapies – incorporation of novel marine based bioceramics and assessment of safety/efficacy equivalence to traditional mammalian-derived biomaterials.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	John Gleeson
2.5.2 Email	john.gleeson@surgacoll.com
2.5.3 Phone	+353877373615
2.5.4 Address	SurgaColl Technologies Limited, Invent, Dublin City University
2.5.5 Post code	Dublin 9
2.5.6 City	Dublin
2.5.7 Country	Ireland
2.6 Legal representative	
2.6.1 Name	John Gleeson
2.6.2 Email	John.gleeson@surgacoll.com
2.6.3 Phone	+353877373615
2.6.4 Address	SurgaColl Technologies Limited, Invent, Dublin City University
2.6.5 Post code	Dublin 9

Project Approved Form	
2.6.6 City	Dublin
2.6.7 Country	Ireland
2.6.8 Date of entering into functions	2016-05-03
2.6.9 Probative document of the Legal representative	Anx_21947/2017 Anx_26036/2017
2.7 Bank account	
2.7.1 IBAN	IE44AIBK93638340365589
2.7.2 SWIFT	AIBKIE2D
2.7.3 Bank	ALLIED IRISH BANK
2.7.4 Bank Account Owner	SURGACOLL TECHNOLOGIES LIMITED
2.7.5 Bank Account Country	Ireland
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21946/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-21
2.8.2 Co-financing declaration	Anx_21941/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-27
2.9.2 State Aid Declaration	Anx_21945/2017
2.0 Partner number	13
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	GNP-AECT
2.2.2 Organization name	Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal
2.2.3 Organization name in English	Galicia North Portugal European Grouping of Territorial Cooperation (GNP-EGCT)
2.2.4 Department	Not applicable
2.2.5 Type of organization	Cross-border organisations
2.2.6 Legal status	Public body
2.2.7 Tax ID	Q1500336A
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	Anx_21950/2017
2.2.8 Website	www.gnpaect.eu

Project Approved Form	
2.2.9 Size of the organization (employees)	6
2.3 Location	
2.3.1 Country	Spain
2.3.2 Sub-Region (NUTS3)	Galicia
2.3.3 City	Vigo
2.3.4 Address	Rua Eduardo Cabello s/n
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: The GNP-EGTC is an entity focused on fostering territorial and transnational cooperation, with high-level relationships with public administration. We have long-standing experience in development and implementation of common public policies for two cross border regions (Galicia and North Portugal).</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.2 Transnational experience	<p>EN: The daily job at GNP-EGTC is always transnational, involving both Spain and Portugal public administrations. In addition, we have experience in developing and managing projects, initiatives and events at international level in coordination with partners of many European and even 3rd countries.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.3 Role in the project	<p>EN: GNP-EGTC will be responsible for implementation of WP3, dealing with capitalization. Leading this WP3 in close contact with the project's leader and coordinating every other partner's activities. As WP3 responsible, will dinamize and stimulate cooperation from the AB and the CIN.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: GNP-EGTC is going to lead WP3, by working deeply with key authorities and relevant experts, both being part of the AB or the CIN. Therefore GNP,EGTC will be responsible for fostering contributions and getting the most out of the expertise of the AB (3.2) and the CIN (3.3) for a deeper development of the project and for guiding policy makers in the scope of valorization of marine products and byproducts in the Atlantic Area with the aim to keep on developing more innovative products. To do so, GNP-EGTC will develop a Capitalization plan (3.1) a Roadmap (3.4), some events (3.5) and a final publication in the project's languages (3.6). Finally, GNP-EGTC will obviously take care of own tasks in WP1 and will work for a great coordination of the partnership and the whole project, will hugely collaborate in WP2 (2.1,2.2, 2.3, 2.5), and will be closely following and offering assistance for remaining WP.</p> <p>ES:</p> <p>FR:</p>

Project Approved Form	
	PT:
2.5 Contact person	
2.5.1 Name	Martín Alonso
2.5.2 Email	malonso@gnpaect.eu
2.5.3 Phone	+34986135126
2.5.4 Address	Rua Eduardo Cabello s/n
2.5.5 Post code	36208
2.5.6 City	Vigo
2.5.7 Country	Spain
2.6 Legal representative	
2.6.1 Name	Maria Galdes
2.6.2 Email	gnpaect@gnpaect.eu
2.6.3 Phone	+34986135126
2.6.4 Address	Rua Eduardo Cabello s/n
2.6.5 Post code	36208
2.6.6 City	Vigo
2.6.7 Country	Spain
2.6.8 Date of entering into functions	2017-02-01
2.6.9 Probative document of the Legal representative	Anx_21953/2017
2.7 Bank account	
2.7.1 IBAN	ES1020805000603040306720
2.7.2 SWIFT	CAGLESMMXXX
2.7.3 Bank	ABANCA
2.7.4 Bank Account Owner	AGRUP. EUROPEA COOP. TERRIT. GALICIA-NORTE PORTUGAL
2.7.5 Bank Account Country	Spain
2.7.6 DTCC Code	
2.7.7 Bank Statement	Anx_21954/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-19
2.8.2 Co-financing declaration	Anx_21951/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-19
2.9.2 State Aid Declaration	Anx_21952/2017
2.0 Partner number	14
2.1 Position in the partnership	Associated partner

Project Approved Form	
2.2 Entity	
2.2.1 Organization acronym when applicable	GAIN
2.2.2 Organization name	Axencia Galega de Innovación
2.2.3 Organization name in English	Galician Innovation Agency
2.2.4 Department	Programmes Department
2.2.5 Type of organization	Regional public organisations
2.2.6 Legal status	Public body
2.2.7 Tax ID	ESQ1500386F
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	
2.2.8 Website	http://gain.xunta.gal
2.2.9 Size of the organization (employees)	115
2.3 Location	
2.3.1 Country	Spain
2.3.2 Sub-Region (NUTS3)	Galicia
2.3.3 City	Santiago de Compostela
2.3.4 Address	Rúa Airas Nunes, s/n
2.4 Partner profile	
2.4.1 Partner skills	EN: GAIN is responsible for structuring, planning, coordinating and implementing research and innovation strategies as well as for the Galician Plan for Research, Innovation and Growth. It's also responsible for the development, coordination, follow up, monitoring and implementation of the regional RIS3 ES: FR: PT:
2.4.2 Transnational experience	EN: GAIN is used to international collaboration, coordinating and monitoring RIS3 implementation together with North of Portugal. GAIN is active in transnational collaborations through innovation networks (ERRIN, the Vanguard Initiative, etc.), and several INTERREG, FP6 and 7, H2020 or ERA-NET projects. ES: FR: PT:
2.4.3 Role in the project	EN:

Project Approved Form	
	<p>To participate, together with the Advisory Board (AB), cooperating and discussing the improvement of politics on R+D+I. GAIN will work for more effective and productive politics, developing the potential of the Atlantic Ocean and overcoming the barriers that hinder the R+D on that specific area.</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: As a member of the AP (Associates Partner) will have the chance to follow closely all achievements and results of the project. Even more, by knowing first-hand the barriers and difficulties that companies and Universities, Research Centers find when dealing with top RDI activities. This close contact with the project will also provide great feedback about the effectiveness and productivity of RDI politics. Collaborating in an international board, formed by highly relevant players on the field, will also contribute for a better development of RDI politics for our territory and for the entire Atlantic Area. Therefore, through advising and discussing with the whole partnership, we will provide our knowledge and opinion to foster blue biotechnology. Finally, we will also participate in some Communication activities, using our website and social networks, as well as our contacts' Database, to disseminate activities, results and conclusions of the project.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Pilar Morgade Saavedra
2.5.2 Email	programas.gain@xunta.gal
2.5.3 Phone	+34981541671
2.5.4 Address	Rúa Airas Nunes, s/n
2.5.5 Post code	15702
2.5.6 City	Santiago de Compostela
2.5.7 Country	Spain
2.6 Legal representative	
2.6.1 Name	Patricia Argerey Vilar
2.6.2 Email	patricia.argerey.vilar@xunta.gal
2.6.3 Phone	+34981541068
2.6.4 Address	Rúa Airas Nunes, s/n
2.6.5 Post code	15702
2.6.6 City	Santiago de Compostela
2.6.7 Country	Spain
2.6.8 Date of entering into functions	
2.6.9 Probative document of the Legal representative	

Project Approved Form	
2.7 Bank account	
2.7.1 IBAN	ES9820800572553040000459
2.7.2 SWIFT	
2.7.3 Bank	
2.7.4 Bank Account Owner	
2.7.5 Bank Account Country	
2.7.6 DTCC Code	
2.7.7 Bank Statement	
2.8 Co-financing declaration	
2.8.1 Document date	
2.8.2 Co-financing declaration	
2.9 State aid declaration	
2.9.1 Date	
2.9.2 State Aid Declaration	
2.0 Partner number	15
2.1 Position in the partnership	Associated partner
2.2 Entity	
2.2.1 Organization acronym when applicable	ANI
2.2.2 Organization name	Agência Nacional de Inovação
2.2.3 Organization name in English	National Innovation Agency
2.2.4 Department	Innovation Policy and Promotion
2.2.5 Type of organization	National public organisations
2.2.6 Legal status	Public body
2.2.7 Tax ID	503024260
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	
2.2.8 Website	www.ani.pt
2.2.9 Size of the organization (employees)	122
2.3 Location	
2.3.1 Country	Portugal
2.3.2 Sub-Region (NUTS3)	Norte

Project Approved Form	
2.3.3 City	Porto
2.3.4 Address	Rua de sagres, 11
2.4 Partner profile	
2.4.1 Partner skills	<p>EN: ANI promotes knowledge transfer through collaboration and cooperation between enterprises and the research institutions. It also supports the definition of innovation policies and the integrated promotion of support to technology transfer, technological innovation, among others.</p> <p>ES: FR: PT:</p>
2.4.2 Transnational experience	<p>EN: ANI boosts the internationalization of the National Research and Innovation System through programmes and initiatives, ensuring the global competitiveness of applied research projects. ANI is a member of the EEN and supports participation in international R+D Consortia (Eureka, Horizon 2020).</p> <p>ES: FR: PT:</p>
2.4.3 Role in the project	<p>EN: To participate, together with the Advisory Board (AB), cooperating and discussing the improvement of politics on R+D+I. GAIN will work for more effective and productive politics, developing the potential of the Atlantic Ocean and overcoming the barriers that hinder the R+D on that specific area.</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: As a member of the AP (Associates Partner) will have the chance to follow closely all achievements and results of the project. Even more, by knowing first-hand the barriers and difficulties that companies and Universities, Research Centers find when dealing with top RDI activities. This close contact with the project will also provide great feedback about the effectiveness and productivity of RDI politics. Collaborating in an international board, formed by highly relevant players on the field, will also contribute for a better development of RDI politics for our territory and for the entire Atlantic Area. Therefore, through advising and discussing with the whole partnership, we will provide our knowledge and opinion to foster blue biotechnology. Finally, we will also participate in some Communication activities, using our website and social networks, as well as our contacts' Database, to disseminate activities, results and conclusions of the project.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Alexandre Almeida
2.5.2 Email	afalmeida@ani.pt

Project Approved Form	
2.5.3 Phone	+351969004541
2.5.4 Address	Campus do Lumiar, Ed. O, 1º, Estrada do Paço do Lumiar
2.5.5 Post code	1649-038
2.5.6 City	Porto
2.5.7 Country	Portugal
2.6 Legal representative	
2.6.1 Name	José Carlos Caldeira
2.6.2 Email	jcaldeira@ani.pt
2.6.3 Phone	+351226167820
2.6.4 Address	Rua de Sagres, 11
2.6.5 Post code	4150-649
2.6.6 City	Porto
2.6.7 Country	Portugal
2.6.8 Date of entering into functions	
2.6.9 Probative document of the Legal representative	
2.7 Bank account	
2.7.1 IBAN	ES9820800572553040000459
2.7.2 SWIFT	
2.7.3 Bank	
2.7.4 Bank Account Owner	
2.7.5 Bank Account Country	
2.7.6 DTCC Code	
2.7.7 Bank Statement	
2.8 Co-financing declaration	
2.8.1 Document date	
2.8.2 Co-financing declaration	
2.9 State aid declaration	
2.9.1 Date	
2.9.2 State Aid Declaration	
2.0 Partner number	16
2.1 Position in the partnership	Associated partner
2.2 Entity	
2.2.1 Organization acronym when applicable	AEI
2.2.2 Organization name	Agencia Estatal de Investigación (MINECO)
2.2.3 Organization name in English	State Research Agency

Project Approved Form	
2.2.4 Department	Not applicable
2.2.5 Type of organization	National public organisations
2.2.6 Legal status	Public body
2.2.7 Tax ID	Q2820338J
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	
2.2.8 Website	http://www.idi.mineco.gob.es/portal/site/MICINN/
2.2.9 Size of the organization (employees)	270
2.3 Location	
2.3.1 Country	Spain
2.3.2 Sub-Region (NUTS3)	Comunidad de Madrid
2.3.3 City	Madrid
2.3.4 Address	Paseo de la Castellana, 162
2.4 Partner profile	
2.4.1 Partner skills	EN: The mission of the Agency is promoting the scientific and technical research through the competitive and efficient allocation of the public resources, the follow up of the funded actions and their impact and the advice on the planning of actions, which work as the tool to implement the R+D policies. ES: FR: PT:
2.4.2 Transnational experience	EN: AEI participates in the national and European RTD policies and in strategies and activities of internationalization. AEI manages competitive bilateral and transnational calls such as H2020. AEI also develops and implements international and European initiatives (JPIs, ERANets, bilateral programs). ES: FR: PT:
2.4.3 Role in the project	EN: To participate, together with the Advisory Board (AB), cooperating and discussing the improvement of politics on R+D+I. AEI will work for more effective and productive politics, developing the potential of the Atlantic Ocean and overcoming the barriers that hinder the R+D on that specific area. ES: FR: PT:

Project Approved Form	
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: As a member of the AP (associates partner) will have the chance to follow closely all achievements and results of the project. Even more, by knowing first-hand the barriers and difficulties that companies and Universities, Research Centers find when dealing with top RDI activities. This close contact with the project will also provide great feedback about the effectiveness and productivity of RDI politics. Collaborating in an international board, formed by highly relevant players on the field, will also contribute for a better development of RDI politics for our territory and for the entire Atlantic Area, Therefore, through advising and discussing with the whole partnership, we will provide our knowledge and opinion to foster blue biotechnology. Finally, we will also participate in some Communication activities, using our website and social networks, as well as our contacts' Database, to disseminate activities, results and conclusions of the project.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Joaquín Serrano
2.5.2 Email	joaquin.serrano@mineco.es
2.5.3 Phone	+34916037742
2.5.4 Address	Paseo de la Castellana, 162
2.5.5 Post code	28071
2.5.6 City	Madrid
2.5.7 Country	Spain
2.6 Legal representative	
2.6.1 Name	Marina Villegas Gracia
2.6.2 Email	dgi@mineco.es
2.6.3 Phone	+34 916037162
2.6.4 Address	Paseo de la Castellana, 162
2.6.5 Post code	28071
2.6.6 City	Madrid
2.6.7 Country	Spain
2.6.8 Date of entering into functions	
2.6.9 Probative document of the Legal representative	
2.7 Bank account	
2.7.1 IBAN	ES9820800572553040000459
2.7.2 SWIFT	
2.7.3 Bank	
2.7.4 Bank Account Owner	

Project Approved Form	
2.7.5 Bank Account Country	
2.7.6 DTCC Code	
2.7.7 Bank Statement	
2.8 Co-financing declaration	
2.8.1 Document date	
2.8.2 Co-financing declaration	
2.9 State aid declaration	
2.9.1 Date	
2.9.2 State Aid Declaration	
2.0 Partner number	17
2.1 Position in the partnership	Partner
2.2 Entity	
2.2.1 Organization acronym when applicable	FCUP
2.2.2 Organization name	FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO
2.2.3 Organization name in English	Faculty of Sciences of the University of Porto
2.2.4 Department	Not applicable
2.2.5 Type of organization	Universities and higher education
2.2.6 Legal status	Not-for-profit private organization
2.2.7 Tax ID	501413197
2.2.7.1 VAT recovery	0
2.2.7.2 If YES explain how?	EN: ES: FR: PT:
2.2.7.3 VAT statement	Anx_21966/2017
2.2.8 Website	https://sigarra.up.pt/fcup/pt
2.2.9 Size of the organization (employees)	388
2.3 Location	
2.3.1 Country	Portugal
2.3.2 Sub-Region (NUTS3)	Norte
2.3.3 City	Porto
2.3.4 Address	Rua do Campo Alegre SN, 4169-007 Porto, Portugal
2.4 Partner profile	
2.4.1 Partner skills	EN: FCUP currently hosts 6 academic departments and 6 high-performing R&D Units. FCUP and the research center affiliated with it, Ciimar, are

Project Approved Form	
	<p>leading units in the research and teaching sciences at the University of Porto and at European scale.</p> <p>ES: FR: PT:</p>
2.4.2 Transnational experience	<p>EN: It has been involved in a number of projects funded by transnational cooperation programmes in the framework of the "European Territorial Cooperation" objective, POCTEP and by the Atlantic Area Programme and by the Operational Programme for Cross-border Cooperation Spain-Portugal.</p> <p>ES: FR: PT:</p>
2.4.3 Role in the project	<p>EN: FCUP will furnish organic fractions obtained from cyanobacterial biomass to other partners, to be tested for different biological activities. In addition, FCUP will test extracts and fractions generated by the consortium in its inhouse anti-obesity assays.</p> <p>ES: FR: PT:</p>
2.4.4 Describe the activities that your organisation is going to implement in the project	<p>EN: FCUP will involve in the three mandatory WP (1-3), and particularly in WP 6: Marine Ingredients for cosmetics, wellbeing and healthcare products. At this respect, FCUP will use strains from a culture collection of cyanobacteria, obtain organic extracts from their biomass and fractionate these extracts into fractions of different polarity. These fractions (315 projected) will be furnished to the consortium to be screened for different biological activities relevant for human health. Taking advantage of a biotechnology pipeline, it will also carry out the screening of extracts and fractions generated in the Project in a series of anti-obesity assays. FCUP will also participate in the characterization of enriched fractions and characterization of their main components.</p> <p>ES: FR: PT:</p>
2.5 Contact person	
2.5.1 Name	Vitor Vasconcelos
2.5.2 Email	vmvascon@fc.up.pt
2.5.3 Phone	+351223401800
2.5.4 Address	Rua do Campo Alegre SN
2.5.5 Post code	4169-007
2.5.6 City	Porto
2.5.7 Country	Portugal
2.6 Legal representative	
2.6.1 Name	António Fernando Sousa da Silva
2.6.2 Email	projetos@fc.up.pt

Project Approved Form	
2.6.3 Phone	+351 220 402 000
2.6.4 Address	Rua do Campo Alegre SN
2.6.5 Post code	4169-007
2.6.6 City	Porto
2.6.7 Country	Portugal
2.6.8 Date of entering into functions	2014-12-03
2.6.9 Probative document of the Legal representative	Anx_21967/2017
2.7 Bank account	
2.7.1 IBAN	PT50003502060000178283036
2.7.2 SWIFT	CGDIPTPL
2.7.3 Bank	CAIXA GERAL DE DEPOSITOS
2.7.4 Bank Account Owner	DINAMIZADOR
2.7.5 Bank Account Country	Portugal
2.7.6 DTCC Code	Porto
2.7.7 Bank Statement	Anx_21964/2017
2.8 Co-financing declaration	
2.8.1 Document date	2017-09-20
2.8.2 Co-financing declaration	Anx_21963/2017
2.9 State aid declaration	
2.9.1 Date	2017-09-20
2.9.2 State Aid Declaration	Anx_21962/2017
3. Brief Summary	
3.1 Brief Summary	<p>EN: The Atlantic Area of European Union is particularly rich in marine resources. Relying on the results achieved previously, the consortium joins research centres and SMEs to propose innovative products for the biomedical field, to be produced not only from a sustainable exploitation of marine resources but also valorising the huge amounts of by-products available in the region. With this, blue biotechnology will be used as a tool for regional smart growth towards harmonization with EU.</p> <p>ES: El área del Espacio Atlántico de la UE es particularmente rica en recursos marinos. Partiendo de resultados anteriores, el consorcio reúne centros de investigación y pymes para proponer productos innovadores en el área biomédica, a través de una explotación sostenible de los recursos marinos, y también mediante la valorización de sus muy abundantes subproductos. Así, la biotecnología azul será usada como una herramienta para el crecimiento regional inteligente, en armonización con la UE.</p> <p>FR: L'Espace Atlantique de l'UE est très riche en ressources marines. Sur la base des précédents résultats obtenus, le consortium réunit des centres de</p>

Project Approved Form

	<p>recherche et des PME pour proposer des produits innovants pour le domaine biomédical, obtenus à partir d'une exploitation viable des ressources marines et de la valorisation de grandes quantités de sous-produits de la région. La biotechnologie bleue sera un outil pour une croissance régionale intelligente, en vue d'une harmonisation européenne.</p> <p>PT: A região do Espaço Atlântico na UE é particularmente rica em recursos marinhos. Com base em resultados anteriores, o consórcio junta centros de investigação e PMEs para propor produtos inovadores para a área biomédica, não apenas a partir da exploração sustentável de recursos marinhos, mas também da valorização dos seus subprodutos, abundantes na região. Assim, a biotecnologia azul será usada como uma ferramenta para o crescimento inteligente, visando uma aproximação à média Europeia.</p>
3.2 Explain eventual modifications in relation to the submitted EOI	<p>EN: No modifications are applicable since the brief summary (3.1) remained intact from first (EOI) to second stage.</p> <p>ES: FR: PT:</p>
4. Project Description	
4.1 Overall objective	<p>EN: The BlueHuman project aims to widen the commercial potential of the Atlantic Ocean on Europe. To achieve this, the project will seek to expand the commercial and scientific potential, beyond current activities mainly limited to fishing and maritime transport, opening the avenue of blue biotechnology with new high added-value solutions. Despite the richness of the biological marine resources from the European Atlantic coast (continental shelf and islands), both in quantity and biodiversity, commercial exploitation is predominantly focused on fishing for food and directing by-products for feed. However, their relevance for other commercial fields has already been demonstrated with pilot examples of marine derived cosmetics, pharmaceuticals and medical device products. Academic partners significantly contributed to this proof-of-concept stage during the previous MARMED project and now aims to collaborate with SMEs to support development of novel products and devices to the global well-being and biomedical markets. In addition, BlueHuman will also seek to influence the actions of other actor's in the region towards the much needed sustainable and smart growth, as identified in EUROPE2020 strategy, by reinforcing the cooperation between academia and industry, with stronger drivers to promote technology-transfer and patent applications, with the ultimate objective of increasing highly-skilled jobs and strengthening the economic tissue, including with new technology-based SMEs.</p> <p>ES: FR: PT:</p>
4.2 Common Challenge	
4.2.1 Common Challenge	<p>EN: The European regions in Atlantic Area have privileged access to marine resources, which despite being a highly valuable asset are not being fully or sustainably exploited. Most current efforts are focused on fishing activities, from which food products result, with derived by-products being mostly</p>

Project Approved Form

absorbed by feed companies in lower added-value applications. Even some efforts recently known of the screening of marine resources for new pharmaceutical entities are not performed in an efficient way. The EU needs to recognise that marine resources and their by-products represent a highly valuable asset, which can play a key role on commercial development activities. In particular the threat of Asian countries on commercial exploitation of marine resources is a reality. Countries from the Atlantic Area have a particular responsibility to the sustainability of marine resources due to their geographic location, but still need to overcome not only the spread of resources (facilities and expertise) across the territory with poor cooperation history, but also the difficulties on collaboration between research centres and industry, still in its infancy in the region, from which academic spin-offs are the representative SMEs examples. BlueHuman will use these challenges as roads to smart growth, by building onto the scientific results from previous initiatives funded by Atlantic Area (project MARMED) to result in new marine-based products for the biomedical and well-being markets.

ES:
FR:
PT:

4.2.2 Explain modifications in relation to the submitted EOI

EN:
Not applicable
ES:
FR:
PT:

4.3 What is new?

4.3.1 What is new?

EN:
BlueHuman proposes the biotechnological valorization of marine resources and by-products with the development of new solutions for the biomedical and well-being market. The potential impact of this approach was assessed in a previous project (MARMED), but the transfer of knowledge to industry and the private investment required to support it is still not well established. Indeed, up to now, the biotechnology-based business arena is predominantly characterized by small companies, spin-offs from Academia. The outputs from previous projects, as MARMED, could not be assimilated by companies with such limited resources, despite their acknowledged value. Hence, BlueHuman gives a robust step further by enrolling private companies together with research centres, working directly on product developments already in course or of major priority for these companies. With this results-oriented approach, it will be possible for the partners to assimilate the jointly achieved project outcomes and at short term have access to the needed investment to apply the new know-how towards the development of new products to the market. In summary, 3 original characteristics of BlueHuman project are identified: Valorization of concrete marine resources and by-products; Progress on different innovation chains within companies of the biomedical sector, with potential to influence new products to the market; and, Strengthening the role of blue biotechnology on Atlantic Area business area.

ES:
FR:
PT:

Project Approved Form	
4.3.2 Explain modifications in relation to the submitted EOI	<p>EN: The innovative aspects of BlueHuman proposal, related with the improvement of current industrial processes, have been clarified. The added-value of the current proposal when comparing to MARMED has been also elucidated.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
4.4 Transnational approach	
4.4.1 Transnational approach	<p>EN: The abundance of marine resources and the relevance they can represent (much more than what they already represent) on economy cannot be explored by just one region or even one country (not enough critical mass). The exploitation of marine organisms needs a synergy between different geographies, together with a multidisciplinary approach. It is an enormous opportunity for the countries composing the Atlantic Area, but they need to overcome the dispersion of resources and the different socioeconomic approaches. Portugal and Spain have great activity on marine resources regarding fisheries for food, but other areas of blue economy (namely biomedical) is still incipient on the industrial arena. On the other side, France, UK and Ireland (also benefiting from contact with multinational companies from USA) have a more active biomedical sector and the socioeconomic development based on a more established platform of innovation. Thus, the cooperation between these two realities will promote the growth of private initiatives for the biotechnological approaches based on marine organisms towards biomedical innovation (to face a growing life expectancy and associated need to extra healthcare), bringing an expectative of exponential economic growth. BlueHuman has partners from all the countries of Atlantic Area, with complementary expertise, supporting the required multidisciplinary collaborative approaches, which can be mimicked later in other EU regions or on other areas and markets.</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
4.4.2 Explain modifications in relation to the submitted EOI	<p>EN: Not applicable</p> <p>ES:</p> <p>FR:</p> <p>PT:</p>
4.5 Cooperation intensity	
4.5.1 Joint development (mandatory)	<p>EN: The proposal has been jointly developed by all the partners that contributed from the best of their knowledge and competencies to define the scope and to identify the key components. The development has been facilitated by the great knowledge of the research organizations in terms of valorization of marine resources and fisheries by-products as well as the business view that the participating companies have of the current and future market in topics related to biomedical developments.</p> <p>ES:</p> <p>FR:</p>

Project Approved Form	
	PT:
4.5.2 Joint implementation (mandatory)	<p>EN: The activities, outputs and results are jointly developed by partners from all the countries. The work plan has been implemented to assure a joint collaboration and an integrated approach. Each partner has a specific complementary role to the others which allows a synergy that eases the achievement of goals.</p> <p>ES: FR: PT:</p>
4.5.3 Joint staffing (mandatory)	<p>EN: Although the project coordinator will play a leading role in Work Package 1, the rest of the WPs will be led by partners from France, UK, Portugal and Spain. At the level of actions, roles have been distributed based on partner specialist areas and functions but sharing responsibilities. Concerning the project execution, all the partners from the 5 Atlantic Area countries will contribute to the Work Plan, as it can be seen from the human resources allocated in the different WPs.</p> <p>ES: FR: PT:</p>
4.5.4 Joint financing (mandatory)	<p>EN: All partners contribute financially to the project resources with an average of 25% of co-funding and generally speaking, there is a balanced involvement of partners from the financial point of view, as shown in the partners' budgets. With a view to a higher benefit of the project the products obtained have been maximized with the minimum investment of costs, searching for the efficiency of the resources available and the maximum efficacy of the planned goals and results.</p> <p>ES: FR: PT:</p>
4.5.5 Joint capitalization	<p>EN: All the partners will contribute to the capitalization of results by developing coordinated actions established in the communication and capitalization strategies. This will include the identification of the members for the Advisory Board (political authorities) and the Collaborative Innovation Network (Academy and industry). They will also participate in relevant conference and forums and they will contribute in the drafting of the reference documents for the policy makers.</p> <p>ES: FR: PT:</p>
4.5.6 Joint enabling of long term effect	<p>EN: The Project planning sets up specific collaborations between groups and companies assuring that the available resources turn out to be useful results for business; and companies are the ones that will make use of it in the long term. On the other hand the participation of the competent national and regional authorities forming the Advisory Board will guarantee the capitalization of the results concerning future RTD policies regarding the valorization of marine resources.</p>

Project Approved Form	
	ES: FR: PT:
4.5.7 Others	EN: The strategy of the Project planning focuses on involving companies from the partnership and also defining in the submitting proposal the specific interactions established between them and the research groups with the aim to devote all the resources to useful developments. Thus, money goes directly to solve matters of real industrial application. The intention is to maximize the territorial repercussion and to achieve a financing/institutional and political sustainability. ES: FR: PT:
4.6 Partnership consistency	
4.6.1 Partnership consistency	EN: The consortium was established by joining a network of strong research centres with diverse but complementary expertise together with active SMEs, regional bodies and authorities, with representatives from the five countries of the Atlantic Area (AA), as required to fulfil the designed strategy aiming smart and sustainable growth of this western European territory. In particular, research centres working both on the valorisation of marine resources and by-products (IIM-CSIC, CIIMAR and UBO) and on the development of biomedical products and applications (UMINHO, UVIGO, UALG, RCSI, UMA) will collaborate synergistically with SMEs established on the international market for marine derived products for well-being and biomedical sectors (YSLAB and JELLAGEN), as well as on medical devices (SURGACOLL), to propose new products and solutions, in a cross-talk between blue and red biotechnologies. This technological effort will be complemented by dissemination actions targeting marine resources processing industries and biomedical industries, managed by a technological centre (CETMAR), together with interaction with authorities (GNP-AECT, AEI, GAIN, ANI) for implementation of improved policies, capitalizing the project results, based on the developed concepts and pilot actions. There will be a balanced distribution of tasks and equilibrated allocation of resources among the partners to use sustainable exploitation of marine resources as driving force for regional development in the AA. ES: FR: PT:
4.6.2 Explain modifications in relation to the submitted EOI	EN: The balance between partners expertise, tasks allocation, leadership role and the reasonable distribution of resources/funding between partners regarding their countries was clarified. BlueHUMAN Project has included as Associated Partners (AP): the Galician Agency of Innovation and the State Research Agency from Spain (GAIN and AEI) and, the National Agency of Innovation from Portugal (ANI). GAIN, AEI and ANI are regional and national institutions, respectively, in charge of preparing innovation policies through the implementation of efficient innovation strategies and programmes. All these AP will actively participate together with the Advisory Board, to improve local, regional, national and international policies of RDI.

Project Approved Form	
	ES: FR: PT:
4.7 Main outputs, results in line with the work plan. Synthesis of the work packages. Target groups	
4.7.1 Main outputs and results	EN: BlueHuman aims to contribute to a more sustainable exploitation of marine resources, both in ecological and economical vectors, by endorsing high added-value applications, namely on the health and well-being sectors. In particular, different technological outputs are foreseen: 3 prototypes of medical devices for bone therapies and wound dressing, 3 matrices for RDI on regeneration of human tissues, 10 new bioactive marine extracts and 2 cosmetic formulations. This will be assessed every six months, having as milestone to have accomplished 1/3 of those numbers after 18 months. If not, during the project midterm meeting, the consortium will make adjustments on the technical strategy: reduce the number of outputs to assure the completion of one prototype in each market area, being one by each participating company, representing a step further on the innovation chains of the enrolled companies, which will be able to assimilate the new valuable know-how and use it further with short to medium-term commercial goals, supported by the associated increase of leverage capacity. The collaborative efforts between research centers and private companies will facilitate the transfer of knowledge, envisaging an increase on patent applications, aiming to result in prototypes of products and solutions corresponding to society needs and with good market receptivity, believed to represent a successful investment to establish new and viable lines of business, replicable and transferable outside the Atlantic Area. From the contacts with the regional, national and European authorities it is foreseen an impact on the definition of new policies and regulations to support the mentioned initiatives, further leading to the improvement of the competitiveness of the Atlantic Area innovation actors. Having Galicia and Portugal as pilot region, it is aimed to have an impact on regional RTD policies, reflected in coming public calls. The interactions at political level will be reinforced, using the RTD roadmap described in the work plan, if changes in policy drivers are not foreseen within 2 years after project start. ES: FR: PT:
4.7.2 Explain modifications in relation to the submitted EOI	EN: Additional details on project outputs and results were given for clarification purpose, namely regarding the impact on the strengthening of innovation chains of industrial partners and consecutively of Atlantic Area. ES: FR: PT:
4.7.3 Who will use the main outputs?	National public organisations, Regional public organisations, Local public organisations
4.7.4 Involvement of target groups	EN: The target groups will be involved in project development through the organizational structure created for this purpose: the Advisory Board (AB) and the Collaborative Innovation Network (CIN). The AB will be composed by

Project Approved Form

political authorities from the Atlantic regions and the EU. The AB guarantees that the project's results focus on the present and future demand of the national and European RDI policies. As illustrative example, BlueHuman project aims to contribute to the revision of the EU regulations on the use of marine by-products (neglected biological resources and seafood by-products), to make possible their use for higher added-value applications whenever proper (safe) industrial manipulation is assured and AB have the lobbying capacity to influence it. Moreover, AB will be a key element for the transnationality and replicability of the results in the Atlantic area. The CIN will gather an innovation critical mass within the European area in the scope of valorization of marine resources and byproducts and of biomedical products and technologies. The CIN will be composed by academics, companies, policy makers and funding agencies, which support the development of European biotechnological valorization of marine resources and byproducts towards the design on innovative products, technologies and services with envisaged impact on human health.

ES:

FR:

PT:

4.8 Long-term effects

4.8.1 Long-term effects

EN:

The cooperation between research centers, as well as with the private companies will be fortified in the future, as happened in previous projects, namely by strengthening the collaborative network CVMar – Multipolar Centre for Valorization of Marine Resources, coordinated by the lead partner and counting already with the participation of some of the partners of the consortium, which will gain a pivotal role in the Atlantic Area regarding marine biotechnology and valorization of marine by-products and underexplored resources. The technological developments within the BlueHuman timeframe will result in products and solutions: prototypes at the end of the project. The partnership, with increased relevance of companies, will continue to promote the results of the BlueHuman project after its end, with new products entering the market, with businesses and economic impact. Effective dissemination to regional and national governing authorities will also take place, having the Galicia-Portugal region as example, with representative organizations (GAIN and ANI) promoting improved policies to support a next generation of innovation efforts on blue biotechnology. Besides, the interaction with local organizations (namely local authorities, as city halls) is expected to allow mimicking this approach in other regions with a lower degree of development or where marine resources have particular relevance.

ES:

FR:

PT:

4.8.2 Explain modifications in relation to the submitted EOI

EN:

The BlueHuman project will increase the visibility of research and innovation in the valorization of marine resources and by-products in Europe, working side by side with EU, national and/or regional policy-makers (see WP3). The improved innovation network of BlueHuman (see WP3, Action3.3.) will provide a long-term collaborative framework with researchers and companies, leading to the creation of new innovation consortia and attracting new funds for the Atlantic area

Project Approved Form	
	ES: FR: PT:
4.8.3 The effects are expected for the next 5 or 10 years?	EN: The effects and benefits expected will be appreciated in 5 years' time. Marine resources valorization is a common problem for the Atlantic Area countries and it is usually included in the Research and Innovation Smart Specialization Strategies (for instance Challenge 1, Priority 5 RIS Galicia). Inside the Atlantic Area there is a lack of territorial coherence regarding this matter. In the Southern countries there are a number of groups specialized in the subject but just a few biotechnology companies while in the other countries the industrial network is flourishing. BLUEHUMAN gather in the partnership organisms from the five countries and intends to establish the collaboration of very different industrial and academic cultures so as to promote in the future the understanding and exchange of knowledge among all of them. The final goal is giving homogeneity to the skills on this matter by maximizing the territorial repercussion (further information on section 4.9.1 http://cvmar.cetmar.org/). By maximizing the resources from the Administration to launch CVMar, it will represent a reference point for other valorization-related companies and groups with complementary skills to join in a way that the capacity to respond will be stronger. It will undoubtedly become the vector and tool that in the long term, either 5, 10 or more years, will use the benefits obtained through this project or others providing Institutional Sustainability with reduced cost. ES: FR: PT:
4.9 Horizontal principles	
4.9.1 Sustainable development (Concrete and real measures to contribute to sustainable development and environment.)	
4.9.1.1 Sustainable development effects	2
4.9.1.2 Description of expected effects	EN: All the known marine and terrestrial ecosystems base their existence, duration and consequently their success in a common factor regarding their inner running mechanisms. On one hand all that is produced is used whatever the way and on the other hand the superior organisms on the top of the trophic pyramid never use more food (energy) than that produced by the base of the ecosystem, which is the primary production. These two principles are the key for life duration and profitability of ecosystems. They both hold and give sustainability to them. The new trends in economic activities –especially those from the primary sector- are focused in a systemic way that guarantees their stability. That's what we call "Sustainable Economy" and "Circular Economy". In brief, it's about basing our interests in the two principles mentioned before which successfully control the ecosystems. The only structurally stable economy likely to survive in time is the sustainable one; in other words, the economy which defends the renovation and care of raw materials which are the basis of any industrial activity and makes the most of the use of by-products. In order to complete the circle proposed by this type of economy it is necessary to highlight the value of the by-products generated by industry and upgrade them to the "raw material" category. Like that they can cover the needs for companies specialized in valorization, able to place in the market

Project Approved Form

high value added products which attract the consumers' attention. A specific knowledge applicable to every type of by-product and process as well as to companies inside the valorization field, which constitute a value chain is necessary to achieve this goal. These two requirements are not always fulfilled and there is a deep lack in the maritime/fisheries sector where BLUEHUMAN is framed. The valorization concept is wide and applies not only to by-products but to underused marine resources and fisheries by-products which, in the Atlantic Area coasts are a big amount. The BLUEHUMAN partnership gathers research groups and companies highly skilled in the use of marine by-products and resources by means of biomedical and cosmetic developments. Their role and goal is increasing the industrial activity through innovation basing on the resources valorization within the common Atlantic field, contributing with new knowledge and collaborating with the companies, which are a key actor to give strength and cohesion to the term sustainability (economic, political, public and private) in the Atlantic Area. The use of fisheries by-products means also a reduction of the harmful effects on the marine environment such as: impact on the trophic ecology, changes in the ecosystem (modification of the biotic community's structure, modification of the habitat, changes in the predator-prey interactions) and impact on the parasitic ecology. The valorization of unknown and underused marine resources will also set the foundation of the development of new companies and work lines for research groups. The synergy companies/research groups will enable and boost future collaborations and projects in this field and will help to keep a permanent innovation. It must be remarked that the NOVOMAR project (POCTEP Program) whose partnership included some of the BLUEHUMAN partners involved the creation of the Multipolar Centre Valorization of Marine Resources and Residues) <http://cvmar.cetmar.org/> , which aimed at integrating the skills of the research groups and make them available for companies and administrations. This tool would be enriched during the BLUEHUMAN project because the number of associated groups and partners would increase and consequently, the critical mass necessary to face this trouble in the Atlantic Area would grow too.

ES:

FR:

PT:

4.9.2 Equal opportunities and non-discrimination (Specific actions foreseen to avoid discrimination and promote equal opportunities)

4.9.2.1 Equal opportunities effects

2

4.9.2.2 Description of expected effects

EN:

The BLUEHUMAN Project will promote equal opportunities from different perspectives: - Gender equality according to the explanation in the next section - Equal opportunities for citizens from the five countries, derived from the strategy of cooperation among them. - In the outsourcing procedures both for the project staff and for the necessary services to develop the planned actions, the compliance with the public procurement rules will be ensured, namely free competition, publicity, transparency, non-discrimination and equal treatment which guarantee that tenders are assessed under the conditions of effective competition. - Given the principles of access and participative approach ruling the project's design and methods the work plan will allow at every moment to act with an inclusive and not hierarchical approach. Facing a more classical approach, based on principles of representativeness,

Project Approved Form

	<p>BLUEHUMAN will offer the opportunity to participate to all types of agents with interests in the aspects undertaken, notwithstanding the membership, position in the organization or anything else. - As there is already a high proportion of women participating in the management of BLUEHUMAN it's expected that the capitalization and communication/dissemination results of the project will serve as an example for society of the promotion of women. Gender innovation has become one of the driving forces in the provision of excellence in innovation and the stimulation of new knowledge and technology.</p> <p>ES: FR: PT:</p>
--	--

4.9.3 Gender equality (Specific actions to ensure equality between men and women)

4.9.3.1 Gender equality effects	2
4.9.3.2 Description of expected effects	<p>EN: The BLUEHUMAN partnership supports the EU policies about the inclusion of the gender perspective and equality according to articles 21 and 23 from the Charter of Fundamental Rights of the European Union and will make an effort to provide equal conditions for men and women in all the project's stages and activities. The project planning and activity is compatible with the Council Resolution 1999/C 201/01 on women and science. Equality criteria were considered to make the partnership with a high % of women in the team. The participation and access to leadership positions will be promoted for women in the actions. If specific gender questions arise during the project execution they will be approached so as to assure equality and assuming if necessary positive discrimination measures to guarantee this goal. The responsibility to take measures for gender equality in all the actions lays exactly on every partner being promoted and reinforced by the decision-making bodies of the project</p> <p>ES: FR: PT:</p>

4.10 Atlantic Strategy

4.10.1 Is the project based on one of the Atlantic strategy specific objectives?	1
4.10.2 If yes, please select one	1

Work page type number	Activity name	Start date	End date
WP Nr. 0 Project Preparation	Preparation	2016-11-01	2017-10-30
WP Nr. 1 Project coordination	Coordination	2018-01-01	2020-12-31
WP Nr. 2 Project Communication	Communication	2018-02-01	2020-10-31
WP Nr. 3 Project Capitalization	Capitalization	2018-01-01	2020-12-31
WP Nr. 4 Marine origin biomaterials for tissue engineering	Marine origin biomaterials for tissue engineering	2018-01-01	2020-12-31
WP Nr. 5 Medical Devices	Medical Devices	2018-01-01	2020-12-31
WP Nr. 6 Marine Ingredients for cosmetics, well-being and healthcare products	Marine Ingredients for cosmetics, well-being and healthcare products	2018-06-01	2020-06-30

WP Nr. 0	Activity	Duration in months	Activity start year and month	Activity end year and month	Activity budget
	Project Preparation	12	2016-11-01	2017-10-30	0.00€
Partners' involvement					
Partner responsible					
Partner involved					

WP Nr.1	Activity	Duration in months	Activity start year and month	Activity end year and month	Activity budget
	Project coordination	36	2018-01-01	2020-12-31	332,617.00€
Partners' involvement					
Partner responsible					
Partners involved					

The goal of this work-package is to assure that the consortium will work as a whole, with each partner acting towards a common objective. UMINHO will act as Project Leader (PL), responsible for the project management and the interaction with the AA governing authorities. Additionally, each WP has a different leader allocated and the group of WP leaders constitutes the Steering Committee (SC), responsible for the executive decisions. Relying on synergistic efforts, the consortium has established two consecutive objectives: i) the successful execution of the proposed strategy; ii) the delivery of the established Outputs envisaging an impact on the AA as described in the respective Results for each action. These will be a measure of the level of efficiency (accomplishment of the plan) and efficacy (the designed plan has the expected results) of the project, to be assessed in a specific action leading with internal project monitoring and evaluation. The main occasions for this exercise will be during GA and SC meetings with the complete consortium and on the elaboration of project reports for AA governing authorities. The Consortium Agreement will be set at the beginning of the project, setting partners rights and obligations. Risk assessment will be made at each project meeting, defining an adequate mitigation plan if necessary. Tasks may be re-allocated by the Steering Committee during the project if a partner is not delivering as expected.

Universidade do Minho	Internal staff	3.45
	Jobs to be created	3
	External staff (outsourcing)	0
	Technical resources involved	3B's facilities at UMINHO are the headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine (TERM), are fully equipped for R+D in biomaterials, TERM and stem cells. In about 3000 square-meters, it includes labs with top-quality equipment, as MALDI-TOF, microCT, FE-SEM, EDS, XRD, AFM, XPS, 3D printers, freeze-dryers, electro-spinning apparatus, mechanical testing machines, cell sorter, RT-PCR, fluorescence confocal microscope, laminar flow cabinets and animal facility.
Centro Tecnológico del Mar – Fundación CETMAR	Internal staff	1.75
	Jobs to be created	0
	External staff (outsourcing)	0.3
	Technical resources involved	Standard Information Technology Equipments (ITE) such as PCs, printers, etc.
Centro Interdisciplinar de Investigação Marinha e Ambiental	Internal staff	
	Jobs to be created	
	External staff (outsourcing)	
	Technical resources involved	
Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas	Internal staff	1.15
	Jobs to be created	1.91
	External staff (outsourcing)	0
	Technical resources involved	Chromatographic analysis GC; HPLC Fermentation processes; Filtration facilities (Micro, DF/UF); Enzymatic and chemical hydrolysis; Pilot plant facilities; Freeze and Spray dryer; Cell culture lab
Université de Bretagne Occidentale	Internal staff	1.09
	Jobs to be created	2.50
	External staff (outsourcing)	0

	Technical resources involved	Extraction and fractionation facilities for the bioactive compounds extraction using sustainable methodologies; Biodimar® platform facilities for the scale up (extraction and bioscreening); Methodologies to assess biological activities (antioxidant, antimicrobial and anti-biofilm); Biochemistry, enzyme engineering, microbiology, molecular biology, proteomic and lipidomic dedicated laboratories; Chemical and structural characterization facilities (FTIR spectroscopy, NMR, Scanning electron microscopy); Rheology facilities
SAS YSLAB	Internal staff	1.63
	Jobs to be created	0
	External staff (outsourcing)	0.31
	Technical resources involved	Cells culture facilities and analytical laboratory (with HPLC equipment, SDS-page electrophoresis...)
Universidade do Algarve	Internal staff	1.192
	Jobs to be created	2
	External staff (outsourcing)	0.667
	Technical resources involved	Cell culture facilities; Zebrafish breeding facilities; Aquarium facilities for fish exposure; Methodologies to assess matrix mineralization and bone formation; Fluorescence microscopy facilities; Real-time quantitative PCR platform; and, tissue processing platform for histology
Universidad de Vigo	Internal staff	1.11
	Jobs to be created	1
	External staff (outsourcing)	0
	Technical resources involved	Durable equipment for bioceramics processing; Laser-assisted workstation for nanoparticle production; Laser spinning equipment for nanofiber production; Equipment for bioceramics characterization (SEM, TEM, XRD, FTIR, XRF, Raman); Cell culture facilities.
Royal College of Surgeons in Ireland	Internal staff	1.8
	Jobs to be created	0.5
	External staff (outsourcing)	0
	Technical resources involved	Facilities for materials development and characterisation including lyophilisation, cleanroom facilities, vacuum ovens, scanning electron microscopy and mechanical testing; Advanced cell culture, histological analysis and core facilities in molecular and cellular imaging including microtome, cryotome, quantitative PCR, etc.; Facilities for the development and characterisation of nanoparticles and analysis of therapeutic release kinetics including spray dryer, high-performance liquid chromatography and dynamic light scattering; Micro-computed tomography, further mechanical testing and confocal microscopy facilities; and, further equipment for advanced imaging and materials characterisation is also available through the Advanced Materials and BioEngineering Research Centre.
Universidade da Madeira	Internal staff	0.15
	Jobs to be created	0.5
	External staff (outsourcing)	0
	Technical resources involved	NMR, FTIR-ATR, Zetasizer, qNANO, spectrophotometers, spectrofluorimeters, microscopes (SEM and fluorescence) and various equipment (laminar flow chambers, etc.) for cell culture.
JELLAGEN PTY LTD	Internal staff	3
	Jobs to be created	1
	External staff (outsourcing)	2
	Technical resources involved	Collagen production system; Basic lab facilities; SDS-PAGE analysis; Freeze drying capabilities; Electrospinning capabilities; Gelation assays and methods; and, Lab-scale collagen extraction rig (20L)
SURGACOLL Technologies Limited	Internal staff	0.5
	Jobs to be created	1
	External staff (outsourcing)	0
	Technical resources involved	Lyophilisation; Microscopy; Cell culture; Methodologies to assess matrix mineralization and bone formation; and, Tissue processing platform for histology
Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal	Internal staff	0.4
	Jobs to be created	0.75
	External staff (outsourcing)	0
	Technical resources involved	Standard Information Technology Equipments (ITE) such as PCs, printers, etc.
Axencia Galega de Innovación	Internal staff	Not applicable
	Jobs to be created	Not applicable
	External staff (outsourcing)	Not applicable
	Technical resources involved	Not applicable
Agência Nacional de Inovação	Internal staff	Not applicable
	Jobs to be created	Not applicable
	External staff (outsourcing)	Not applicable
	Technical resources involved	Not applicable
Agencia Estatal de Investigación (MINECO)	Internal staff	Not applicable
	Jobs to be created	Not applicable
	External staff (outsourcing)	Not applicable
	Technical resources involved	Not applicable
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO	Internal staff	0.33
	Jobs to be created	1
	External staff (outsourcing)	0
	Technical resources involved	Chemistry - Fume hoods, rotavapor, nitrogen drying apparatus, freeze-dryer, high-vacuum pump, speed vac; LC-MS; HPLC. Bioassays - Biosafety cabinet, incubators, cell counter, micro plate reader. Other - Culture collection (LEGEcc).

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).			
Action nr. 1	Action title: Project management and reporting	Start date: 01-2018	End date: 12-2020
	Action description: Project Management aims to support the successful execution of the project. PL will be responsible by coordination of project activities and operational tasks (contractual issues, assisting technical and financial reporting, timely delivering of project outputs). SC will perform the project monitoring and propose corrective actions if needed. GA will validate decisions by consensus. Biannual project technical reports are planned, with claiming for reimbursement of expenses at least once a year.		
Deliverables	Outputs title: Management bodies and Project reports	Outputs description: The 2 main management bodies will be established: the Steering Committee, composed by all WP leaders, and the General Assembly, composed by all partners. The consortium will generate a report every 6 months, claiming costs every year.	Indicators: CO41#3 CO42#8 OA2#6
	Expected results title: Successful execution and adequate reporting	Expected results description: With the management methodologies and tools, the consortium will be able to execute successfully the established plan. The several reports will demonstrate such execution, which can be mimicked in future endeavours to strengthen AA.	
Action nr. 2	Action title: Consortium agreement and meetings	Start date: 01-2018	End date: 12-2020
	Action description: A consortium agreement will be designed, encompassing the rights and obligations of each partner regarding technical tasks, budget allocation, intellectual property issues, reporting, communication and capitalization of results. This consortium will be set in the beginning of the project. Moreover, consortium (and particularly SC) meetings will be organized every 7 months hosted by different partners, starting with the kick-off meeting at PL premises, to discuss the progress of the project.		
Deliverables	Outputs title: Consortium Agreement and Project meetings	Outputs description: A consortium agreement will be set at the beginning of the project to establish boundaries for the action of the partners. The outcome of the collaborative efforts between partners will be assessed during the several project meetings foreseen.	Indicators: OA1#6
	Expected results title: Project consortium	Expected results description: During the project execution, the collaborative links between partners will be strengthened, establishing a true consortium capable of working as a whole towards a common goal. This network will be kept active for future endeavors on marine biotech.	
Action nr. 3	Action title: Project monitoring and evaluation	Start date: 01-2018	End date: 12-2020
	Action description: BlueHuman strategy guidelines are established in the present proposal and details will be further discussed in the kick-off meeting. There will be a continuous communication between partners to understand if the strategy is being followed (project monitoring), particularly on project meetings. During these meetings, an assessment of the proposed objectives and level of accomplishment of outputs and quantified indicators (project evaluation) will be made, when corrective actions may be needed.		
Deliverables	Outputs title: Assessment of project execution	Outputs description: The project execution will be assessed regarding the accomplishment of the established objectives and quantified indicators. A report will be elaborated with details on the contributions of BlueHuman to the policies established in the AA Programme.	Indicators: PI01#1 PI03#1 OA2#1
	Expected results title: Accomplishment of project indicators	Expected results description: An assessment of the accomplishment of the designed BlueHuman objectives, quantified as project indicators, will be made. The respective contribution for the AA Programme objectives will be addressed, giving clues for future policies on innovation.	

WP Nr.2	Activity	No	Duration in months	Activity start year and month	Activity end year and month	Activity budget
	Project Communication		33	2018-02-01	2020-10-31	189,784.00€
Partners' involvement						
Partner responsible		2				
Partners involved		1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17				

The communication and dissemination strategy includes goals, target groups and tools. It details the activities needed to spread the project's results and to ensure the coordination among the partners with a scientific or a business character. The indicators will allow to monitor and implement this strategy. CETMAR will ensure the development of a transversal strategy, coordinating the efforts done by all other Work Packages, especially the WP3 involved in capitalization. CETMAR will lead the internal communication, addressed to project partners, and the external communication to increase awareness among the target audience and stakeholders. The mix of internal and external actions will offer coherence between the activities and the different messages transmitted to the target public. The planned actions include the launching of a website (containing a video, a flyer and a newsletter) to reach the general public, the maintenance of social media profiles addressed to scientists, policy-makers and business managers, the presentation of a poster and flyer in events, the organization of face-to-face seminars for stakeholders. All the partners will participate in actions 2.1, 2.2, 2.3 and 2.5. In action 2.4, only CETMAR and UBO will participate. These actions will be constantly monitored (Google Analytics) to adapt the resources and achieve the goals of the communication strategies.

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).			
Action nr. 1	Action title: Development and implementation of the communication and dissemination strategy	Start date: 02-2018	End date: 10-2020
	Action description: A document of dissemination strategy (Communication and Dissemination Plan; the PC henceforth) will be created at the initial stage of the Project and updated all along the Project. It will contain the methods, protocols, tools and process_templates, reports,		

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).				
	presentations, etc., used to communicate the project's results. It will also guarantee a coordinated strategy between the companies and the research groups of the consortium. A specific logo will be designed for the project.			
Deliverables	Outputs title: Communication Plan	Outputs description: Deliverable containing the methods, tools and processes used by the consortium to establish a uniform and corporative communication and dissemination strategy. An updated draft will be attached to every activity execution report of WP1.	Indicators: OA2#1	Target:
	Expected results title: To enhance the project's communication and transfer ability	Expected results description: The PC sets the guidelines, shared among all the partners, to maximize the project's scope and social repercussion in terms of communication and dissemination with the minimum effort through the different tools used.		
Action nr. 2	Action title: Website, Social Networks and Mass Media	Start date: 02-2018	End date: 10-2020	
	Action description: CETMAR will be responsible to develop the official website of the project; it will be designed according to the communication plan. There will be also dissemination of the project via social networks (Twitter, LinkedIn, and Google+) which will allow a quick and global spread of the project news. All these channels will be linked to the website. Additionally there will be press news and interviews published in the mass media.			
Deliverables	Outputs title: Definition and follow-up of the reach of the BLUEHUMAN Website	Outputs description: Deliverable containing the values that measure the activity and the impact of the website along the project's life: visitors, downloads, etc.	Indicators: OA3#1 PI04#1	Target:
	Expected results title: Quick and global communication of the project's news	Expected results description: Highly efficient communication vector which reinforces the project's look and transfer: great media repercussion at a low cost, higher internationalization. It also increases the web traffic and improves the SEO.		
Action nr. 3	Action title: Project Promotional Video	Start date: 06-2018	End date: 12-2018	
	Action description: Several-minute-length video showing the aim of the Project, the determined goal and in general all the project's issues. It'll be uploaded to the CETMAR's YouTube channel and there'll be an access through a link in the BLUEHUMAN website. There will be also more informative videos (3-5 minutes clips) to achieve a greater dissemination of the Project and its goals. They'll have a more specific content about the project actions.			
Deliverables	Outputs title: Promotional Video BLUEHUMAN	Outputs description: It will contain formal aspects regarding the composition of the partnership and the context of this project and others linked to circular economy, blue growth and highly efficient use of the marine natural resources.	Indicators: OA3#3 PI04#1	Target:
	Expected results title: Visual communication to complete the written and oral	Expected results description: Very efficient high impact tool to disseminate the results. It transfer ideas and concepts quickly and easy to understand, with immediate effects. It put emphasis on the importance of an idea or concept.		
Action nr. 4	Action title: Organization of communication events	Start date: 10-2018	End date: 06-2020	
	Action description: A face-to-face event allows the communication between speakers/participants and offers the possibility to discuss in depth different issues of the treated subject. It promotes some dynamics that generate other initiatives linked to the project. There will be two seminars along the project whose topics are still to be defined but always based on the valorisation of marine resources and devoted to some of the fields contained in the different actions defined.			
Deliverables	Outputs title: Report about the organized seminars	Outputs description: There will be a report per event on: goals, program, dissemination material (leaflet and poster), results (no. of participants, presentations, and pictures), statistics (beneficiaries, male/female, type of organism) and satisfaction surveys.	Indicators: PI04#2 PI05#90	Target:
	Expected results title: Direct communication with stakeholders	Expected results description: They provide the communication with stakeholders offering the possibility of a direct transfer. They promote a dynamics that generate other Project-linked initiatives. It increases the social, public and business leverage of innovation.		
Action nr. 5	Action title: Development and distribution of communication material	Start date: 04-2018	End date: 10-2020	
	Action description: Newsletter: A biannual newsletter to keep target audiences and end-users aware of the development and the results obtained by the project. It is also a way to drive traffic to the website, enhancing the SEO of the website together with the social media activity. Flyer: Business card of the project. Information: goals, problematic, abilities and background of the partnership. Dissemination material: posters and leaflets (in all languages). Distribution among all the stakeholders identified.			
Deliverables	Outputs title: Flyer, poster and leaflets of BLUEHUMAN Project. Summary report of the newsletters published	Outputs description: Flyer and dissemination materials: documents compiling different aspects of the Project; available in digital format and in all Atlantic languages, to use at any seminar. Newsletter: analysis and quantification of subscribers and visitors.	Indicators: OA3#5 PI04#2	Target:
	Expected results title: Enhancement of the communication value, increment of the interest and demand of results,	Expected results description: The goals are to: transmit, reinforce and assure the project's image; catch the target group's attention; and, producing a long term impact on the stakeholders relationship.		

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).	
	and stakeholders loyalty to the project

WP Nr.3	Activity	No	Duration in months	Activity start year and month	Activity start end and month	Activity budget
	Capitalization		36	2018-01-01	2020-12-31	218,312.00€
Partners' involvement						
Partner responsible		13				
Partners involved		1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17				

Describe how the capitalization strategy will be implemented during the project life-time including an explanation of how partners will be involved (who will do what).

The capitalization strategy will work to support the government-industry-academia cooperation (triple-helix model) to enhance the establishment and development of bio-based economy in the field of marine valorization in the Atlantic Area. It includes the creation of an Advisory Board (AB) composed of national and European political authorities of the Atlantic Area. A Collaborative Innovation Network (CIN) gathering all the relevant actors in valorization of marine resources and byproducts will be constituted. A BlueHuman RoadMap will be developed to be a reference document for policy makers on the future strategic goals regarding innovation in the biotechnological valorization of marine resources. Capitalization events and publications will be addressed to the AB, Associate Partners (AP) and CIN to maximize the transfer and replicability of the results obtained in the Project. Led by AECT all the project partners will identify and contact national and/or regional authorities, as well as relevant experts and the appropriate industry representatives, in order to constitute the AB and the CIN. All the BLUEHUMAN partners will be invited to participate in the RoadMap and will nominate a leader for every challenge identified in the project. Likewise a direct communication line will be established with the AB to develop the challenges and with the members of the CIN to include their assessments in the RoadMap.

The BlueHuman Project includes as Associated Partners (AP) the AEI, GAIN and ANI, which are regional and national organisms in charge of preparing innovation policies through the implementation of efficient innovation strategies and programmes. The Advisory Board (AB) will be composed of political authorities as well as relevant experts from the project's partner regions who could not be included as AP during the preparation of the proposal. The AB and the AP will offer advice on the political relevance of the project's results and goes along the execution of the project to assure its development according to the innovation policies and to promote the transfer to other locations in the Atlantic Area. The BlueHuman Roadmap will be a tool to allow policy makers identify, evaluate and select innovative strategic alternatives to achieve an integrated approach of the biotechnological valorization of marine resources and byproducts. The triple helix model developed in BlueHuman project involve the decisive and active participation of policy-makers, academics and industry, as key elements for establishing an open collaborative strategy to attract talent, financial resources and ideas aiming to create new products for the European markets.

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).				
Action nr. 1	Action title: Development and implementation of the capitalization strategy		Start date: 01-2018	End date: 09-2018
	Action description: The Capitalization Plan (CP) will be a common guide for all the project partners, allowing synchronicity between planning and execution of the tasks described in the following actions of this WP. The CP will describe in detail the actions and the tools, bearing always in mind the other project activities. CP will be performed in close collaboration with the Communication Plan, ensuring the highest number of synergies among the related activities and avoiding overlaps.			
Deliverables	Outputs title: BlueHuman Capitalization Plan	Outputs description: Report of the tasks to be developed through meetings, seminars and presentations addressed to targeted decision-makers, politicians, and relevant regional level agencies for RTD. An updated draft will be attached to every activity execution report.	Indicators: OA2#3	Target:
	Expected results title: Capitalization strategy to facilitate the transfer and replicability of results	Expected results description: CP will be developed to transfer the results of the project, facilitate its replicability and promote new investment of funds from UE and national agencies, with the aim to improve the innovation of companies and public organisms.		
Action nr. 2	Action title: Constitution of BlueHuman Advisory Board		Start date: 01-2018	End date: 10-2018
	Action description: The Advisory Board (AB) will be composed of key authorities (political authorities) from the Atlantic regions and the EU. The AB will help to guide the activities and products of the project, so that they are in line with the needs and priorities of the agencies and responsible organizations. The AB will receive regular information, meet periodically with the steering committee and give specific advice. The conclusions obtained by the AB will be integrated along the project way.			
Deliverables	Outputs title: Advisory Board: members and functions	Outputs description: Document containing the members of the AB with a detailed description of background and position. It will include a detailed description of the tasks which require their collaboration and presence.	Indicators: OA2#1	Target:
	Expected results title: Involvement of regional and national policy makers	Expected results description: The AB will guarantee that the project's results focus on the present and future demand of the national and European R&I policies; and will be a key element for the		

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).				
		transnationality and replicability of the results in the Atlantic area.		
Action nr. 3	Action title: Collaborative Innovation Network (CIN)		Start date: 01-2018	End date: 12-2020
	Action description: The CIN will gather an innovation critical mass within the European area in the scope of valorization of marine resources and byproducts with the aim to keep on developing more innovative products. More emphasis will be put on reaching the participation of the specialized industry and SMEs. Related European projects, networks and platforms will be identified to establish systems for cooperation, to identify synergies and to set up a light method for the information exchange.			
Deliverables	Outputs title: Technical report of the Collaborative innovation network	Outputs description: A technical report will be produced per year describing the structure and organization of the thematic network, the updated member list and the activities performed in each period.	Indicators: OA2#3	Target:
	Expected results title: Managing Collaborative Technological Innovation	Expected results description: To strengthen and increase collaboration between companies and researchers from the different institutions involved in the network. To identify new opportunities to generate innovation and develop the bases of new innovative projects.		
Action nr. 4	Action title: BlueHuman Roadmap for Research and Innovation		Start date: 01-2020	End date: 12-2020
	Action description: With the results obtained, new challenges of interest will be identified. Different work teams (formed by partners, AP, AB and CIN) will work together to provide an effective framework for carrying out strategic thinking processes and for collectively building a vision of the future that can help companies and national and EU authorities to develop policy measures addressing the challenges in biotechnological valorization of marine resources and byproducts.			
Deliverables	Outputs title: After project action plan (RoadMap)	Outputs description: The roadmap will be an action plan describing a planned series of actions, tasks and steps designed to achieve an objective. The selected challenges will include current, market trends and more general issues, such as environmental and social aspects	Indicators: PI03#1	Target:
	Expected results title: After project action plan addressed to policy makers	Expected results description: The Roadmap will help to identify the strength of innovation in the biotechnological valorization of marine resources and byproducts, to increase the uptake of the UE funds addressed at public and business innovation in this topic.		
Action nr. 5	Action title: Capitalization events: organization and participation		Start date: 01-2018	End date: 12-2020
	Action description: Participation of the partners in events, such as congresses or seminars, represents an opportunity to introduce project results, exchange experiences, and do networking with other related projects. BlueHuman will organize three events to expand and reinforce the network of researchers, industry, policy makers and funding agencies to support the development of European marine biotechnological valorization. Events will be organized in Cardiff (Nov-18) Vigo (Jul-19) and Brussels (early 2020).			
Deliverables	Outputs title: Capitalization events of BlueHuman Project	Outputs description: Deliverables describing the participation of the partners in different activities and detailed report of the specific events of capitalization organized.	Indicators: PI04#15 PI05#40	Target:
	Expected results title: Transfer and replicability actions	Expected results description: This action will give a chance to influence the future of the biotechnological valorization and promote the triple-helix model of cooperation (Government-industry-academy) for the development of new bio-based economy clusters in the EU.		
Action nr. 6	Action title: Capitalization publication: improving innovative policies on biotechnological valorization of marine resources and byproducts.		Start date: 10-2019	End date: 12-2020
	Action description: A final document about Innovation Policies in the field of the biotechnological valorization of marine resources and byproducts will be prepared in collaboration with the partners, AP, AB and CIN. This document will be published in all languages of the Atlantic Area to promote policies towards a model of knowledge-based blue economy. The publication will be distributed by participants as well as sent to other players and policy makers in the Atlantic Blue bio-economy.			
Deliverables	Outputs title: BlueHuman findings: Recommendations for improved innovative policies on biotechnological valorization	Outputs description: Publication regarding capitalization of the project's results for improved and more efficient Innovation policies, published in 4 languages from the Atlantic Area, to distribute among policy makers.	Indicators: PI03#4	Target:
	Expected results title: Support to the development of sector policies	Expected results description: To identify the latest innovation trends		

Please describe actions (max. 6) and deliverables within the Activity (the system must allow create a maximum of 6 actions).

	to identify new innovative products and processes	obtained in Bluehuman project by promoting a "win-win" relationship among government, industry and academy, for implementing policies and programmes that support the RDI in biotechnological blue valorization.		
--	---	--	--	--

WP Nr. 4	Activity	No	Duration in months	Activity start year and month	Activity end year and month	Activity budget
	Marine origin biomaterials for tissue engineering	36		2018-01-01	2020-12-31	628,906.00€
Partners' involvement						
Partner responsible		11				
Partners involved		1,4,5,6,9,10,11,12				

Due to limited self repair ability of human tissues, tissue engineering (TE) arises as the only hope to treat certain pathologic conditions. TE consists in the development of appropriate scaffolds able to support cell growth, assisted by regenerative cues, creating the right microenvironment for the regenerative process to take place. This work-package (WP) aims to address the value of marine materials (with reduced risk of zoonosis) for medical application by developing innovative biomaterials and assess their performance in tissue regeneration context. WP4 comprehends actions in which purified (towards medical grade) marine materials produced by EU Companies (as the WP leader) or Research Institutions will be used for the development of appropriate scaffolds, drug delivery vehicles and combined on advanced therapies, as proof of concept. The enrolled companies will be capable to integrate the new know-how on their industrial processes (enhanced financing absorptive capacity), towards the development of new commercial products, , namely supported by the associated higher stronger leverage power. Jellagen and SurgaColl represent pilot actions, being replicable and transferable outside Atlantic Area regarding the consolidation of blue economy and biomedical sector at European level. Moreover, with improved competencies, the participating institutions will strengthen their capacity to access to public funds (namely Horizon 2020) and thus their role as innovation actors.

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).

Action nr. 1	Action title: Hydrogels based in jellyfish collagen for cartilage therapies		Start date: 01-2018	End date: 12-2020
	Action description: Collagen type II forms the structure of cartilage and its destruction is an important factor in promoting cartilage degeneration. Hydrogels have demonstrated unique characteristics as platforms to support de novo tissue formation. Hydrogels based in low immunogenic collagen type II-like, eco-friendly obtained from jellyfish (Jellagen) or marine by-products, as skeletons of cartilaginous fish (IIM-CSIC) will be developed (UMINHO) for the engineering of cartilage tissue towards regeneration.			
Deliverables	Outputs title: Collagen from jellyfish and cartilaginous fish and derived hydrogels	Outputs description: Characterization of the isolated collagens; different preparation methods assayed for the obtaining of hydrogels, which performance towards cartilage regeneration will be displayed in vitro. Project report and scientific publications	Indicators: OA1#2 PI01#2 PI02#2 OA2#2	Target:
	Expected results: Hydrogels based in jellyfish collagen promoting cartilage regeneration	Expected results description: Type II-like collagens will be obtained from different marine resources. Further, adequate processing technologies will be designed for the production of marine collagen-based hydrogels. Such hydrogels will enable cartilage tissue engineering.		
Action nr. 2	Action title: Crosslinking of collagen assisted by transglutaminase		Start date: 06-2018	End date: 12-2019
	Action description: The aim is to reinforce the structure of marine collagens type I – including the one produced by YSLAB – using optimized transglutaminase crosslinking process in order to strengthen the mechanical properties and to control the size of the voids in the porous matrix. The resulting marine collagen scaffolds, with improved mechanical properties, constitute a platform alternative to the ones based in mammalian collagens, which would facilitate cell adhesion and proliferation in TE approaches.			
Deliverables	Outputs title: Cross-linked collagen prototypes envisaging the tissue engineering, cosmetics or wound-healing markets. Scientific publications	Outputs description: 2 prototypes of optimized cross-linked collagens (from salmon and shark) with a technical annex describing rheological and structural properties of derived hydrogels and sponges. The more relevant results will be published as scientific publications	Indicators: OA1#2 OA2#2 PI01#2 PI02#2	Target:
	Expected results: Control and understanding of the collagen crosslinking process mediated by transglutaminase	Expected results description: Improved marine collagens and scaffolds supporting the adhesion and proliferation of specific cells. A better understanding of enzymatic crosslinking and its impact on rheological and structural properties based on up-to-date analytical techniques.		
Action nr. 3	Action title: Functionalization of biomaterials with delivery devices for cartilage regeneration		Start date: 01-2019	End date: 12-2020
	Action description: Transforming growth factor # (TGF-#) and basic fibroblast growth factor (bFGF) are known to promote chondrogenesis. Inconveniently, these factors present a short half-life in vivo, while a prolonged stimulation can provoke undesirable side effects. Nanoparticles will be developed (UMadeira and UMinho) to protect and deliver those factors, avoiding degradation and controlling release. Nanoparticles will be further included in the prepared hydrogels as theranostic agents (Jellagen, UMINHO).			
Deliverables	Outputs title: Growth factor loaded nanoparticles. Hydrogels functionalized with nanoparticles. Scientific publications.	Outputs description: TGF-# and bFGF loaded nanoparticles will be obtained, characterized and further included in the collagen-based hydrogels. Stem cells will be also included to enhance performance regarding cartilage regeneration. Relevant results will be published.	Indicators: OA1#2 PI01#3 PI02#3 OA2#1	Target:

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).			
	Expected results: Cartilage regeneration promoted by marine-based collagen hydrogels functionalized with nanoparticles	Expected results description: Nanoparticles will be developed and loaded with TGF-# and bFGF (growth factors). Incorporation of the nanoparticles in the marine collagen-based hydrogels (from A.1) will, together with stem cells, promote the formation of new cartilage-like tissue.	
Action nr. 4	Action title: Blends of marine origin collagen and chondroitin sulfate for encapsulation of chondrocytes and stem cells	Start date: 10-2018	End date: 12-2020
	Action description: The glycosaminoglycan (GAG) chondroitin sulfate (CS) is a key component of cartilage and was shown to have positive biological effects towards chondrogenesis. During this task marine origin CS will be produced from cartilaginous fish (IIM-CSIC) and combined with marine collagen (UMINHO), to obtain hydrogels capable of encapsulating chondrocytes and stem cells (UMINHO, RCSI) for cartilage regenerative approaches. Hydrogel performance will be addressed in vitro and in vivo (RCSI, SurgaColl).		
Deliverables	Outputs title: Marine chondroitin sulfate / collagen blends for the encapsulation of chondrocytes and stem cells. Scientific publications.	Outputs description: Different CS-collagen blends will be obtained and characterized. Chondrocytes and stem cells will be encapsulated on the obtained hydrogels, yielding enhanced systems capable of supporting cartilage regeneration. Relevant results will be published.	Indicators: OA1#2 PI01#2 PI02#2 OA2#1 Target:
	Expected results: Cell-laden polymer blends supporting cartilage regeneration	Expected results description: Chondroitin sulfate will be produced from cartilaginous fish by-products. CS will be further blended with marine collagens and encapsulate chondrocytes and stem cells. The cell-laden biomaterials will promote the formation of cartilage-like tissue.	
Action nr. 5	Action title: Blends of marine origin biopolymers as platforms for wound regeneration	Start date: 01-2018	End date: 12-2020
	Action description: The aim is the development of biomaterials as platforms to explore approaches for regeneration of skin on wound healing assessment. Marine origin biopolymers will be used to develop gels and sponges: collagen from jellyfish (Jellagen) or fish by-products (IIM-CSIC) will be blended (and crosslinked) with elastin (UMINHO) and hyaluronic acid (IIM-CSIC); defined growth factors and stem cells will be incorporated as advanced therapy for wound healing (UMINHO), assessed in adequate animal model.		
Deliverables	Outputs title: Blends of collagen and other marine biopolymers as platforms for skin regeneration. Cell-laden biomaterials as advanced therapies with enhanced performance. Reports and scientific publications.	Outputs description: Development of crosslinked collagen-based biomaterials by blending with elastin and hyaluronic acid. Supplementing with growth factors enhance performance on skin regeneration towards wound healing. Scientific papers showing promising results.	Indicators: OA1#2 PI01#1 PI02#2 OA2#1 Target:
	Expected results: Marine origin polymers used to produce biomaterials capable to induce skin.	Expected results description: Successful combination of jellyfish collagen with other marine origin biopolymers as gels or sponge formulations capable to deliver growth factors and cells in a controlled manner to trigger and support skin engineering in vitro and in animal model.	

WP Nr. 5	Activity	No	Duration in months	Activity start year and month	Activity end year and month	Activity budget
	Medical Devices		36	2018-01-01	2020-12-31	691,075.00€
Partners' involvement						
Partner responsible		12				
Partners involved		1,4,5,8,9,11,12				

The present WP is focused on medical devices based in marine origin materials envisaging therapies for bone, cartilage and skin pathologies. From one side, systems based in marine materials similar to medical devices owned by SurgaColl (HydroxyCollTM and ChondroCollTM) will be developed as potential alternatives; moreover, innovative systems will be also addressed. Besides bone therapies, wound dressings will be also developed, as potential medical devices, using a combination of jellyfish collagen from Jellagen Pty Ltd (JPL) with gellan gum and functionalized with chitosan or other biocompounds with anti-microbial properties. The aim is to demonstrate the high potential of materials isolated from marine by-products for this high added-value sector of medical devices, delivering prototypes of functional marine biomaterials, which industrial production can be latter on (after project timeframe) integrated in the companies' innovation chains (enhanced financing absorptive capacity), towards the development of new commercial products, namely supported by the associated higher stronger leverage power.

SurgaColl and Jellagen represent pilot actions, being replicable and transferable outside Atlantic Area regarding the consolidation of blue economy and medical devices sector at European level.

Moreover, with improved competencies, the participating institutions will strengthen their capacity to access public funds (namely Horizon 2020) and thus their role as innovation actors.

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).			
Action nr. 1	Action title: Scaffolds of shark collagen and shark calcium phosphates for bone regeneration	Start date: 01-2018	End date: 03-2019
	Action description: Raw materials currently considered as fish by-products will be processed, isolating collagen (IIM-CSIC) and calcium phosphates (UVIGO) from skins and teeth of shark (Prionace glauca), using previously established methods. From their combination 3D structures will be obtained (UMINHO) aiming to assess and demonstrate the potential of new natural-derived composite to support the culture of osteoblast cells, promote osteogenic differentiation of stem cells and further regeneration of bone tissue.		
Deliverables	Outputs title: Collagen:calcium phosphates scaffolds for bone repair. Scientific publications on the obtained results	Outputs description: Development of optimized scaffolds with ability to promote osteogenic differentiation of stem cells as prototype of medical device. Relevant results published as scientific papers	Indicators: PI01#1 PI02#1 OA1#2 CO41#1 Target:
	Expected results: Osteogenic 3D Scaffolds	Expected results description: It is expected to have fully characterized materials with suitable properties. Biologic assays will demonstrate the ability of the 3D structures to promote osteogenic differentiation of stem cells responding to the demands in orthopedically field.	
Action nr. 2	Action title: Functional scaffolds based in collagen-based composites	Start date: 10-2018	End date: 12-2020

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).			
	Action description: Using the previously produced scaffolds (action 5.1), their functionalization with DNA and BMPs (Bone Morphogenetic Proteins) will be addressed (UMINHO, UBO and RCSI) to increase efficiency, namely regarding the differentiation of stem cells towards osteogenic lineage and subsequent formation of bone tissue. The performance of the improved prototypes will be addressed in adequate animal models (RCSI and SurgaColl) and compared with the current SurgaColl medical device HydroxyCollTM.		
Deliverables	Outputs title: Functionalized collagen:calcium phosphates scaffolds for bone repair. Scientific publications of the obtained results	Outputs description: Functionalization of previously produced scaffolds with DNA and BMP to promote bone formation, as improved prototype of medical device. Relevant results published as scientific papers	Indicators: PI01#2 PI02#2 OA1#2 CO41#1 Target:
	Expected results: Successfully functionalized scaffolds	Expected results description: Biologic in vitro assays will demonstrate a good cellular crosstalk in co-cultures. After implanted scaffolds, we expect to see better results in presence of the functionalized scaffolds when compared with the controls (non functionalized scaffolds).	
Action nr. 3	Action title: Trilayered scaffold based in marine origin materials for regeneration of osteochondral defects	Start date: 03-2019	End date: 12-2020
	Action description: Complex tissue defects involving both cartilage and bone require advanced therapies, as trilayered scaffolds: ChondroCollTM, from SurgaColl. This action aims to assess the potential of marine origin materials for this goal, developing alternative structures (UMINHO): composites (A5.1, A5.2) as bone-mimicking layer, type I collagen:hyaluronic acid as intermediate layer, type II collagen:chondroitin sulfate as cartilage-mimicking layer, evaluating performance in animal models (RCSI, SurgaColl).		
Deliverables	Outputs title: Trilayered scaffolds for osteochondral defects. Reports and scientific publications of the obtained results	Outputs description: Trilayered Scaffolds inducing both bone formation and cartilage regeneration, as prototype of marine-based medical device. Relevant results published as scientific papers	Indicators: PI01#1 PI02#2 OA1#2 CO41#1 Target:
	Expected results: Effectiveness on regeneration of osteochondral defects	Expected results description: The effectiveness of the multi-layered marine collagen-based scaffolds in the treatment of osteochondral lesions will be shown. It is expected from this biomaterial an improved regenerative response when compared with the traditional therapies.	
Action nr. 4	Action title: Dressings for skincare application, as wound protection	Start date: 06-2018	End date: 12-2020
	Action description: The goal of this action is to develop medical devices that can be exploited for future use in skin protection and wound dressings. For that, high-purity jellyfish collagen (Jellagen) will be combined with gellan gum to produce porous membranes/films (UMINHO, IIM-CSIC), with enhanced cohesiveness and mechanical properties, for wound protection and moisturizing. The devices will be functionalized with chitosan and other bioactive compounds (A6.2) for wound healing improving.		
Deliverables	Outputs title: Prototypes of each type of structure (membranes and films). Functionalized collagen-based devices as wound dressing. Reports and scientific publications about the results obtained	Outputs description: Prototype of medical devices based on collagen and gellan gum. Functionalization of structures with anti-microbial components for enhanced performance. Periodic reports describing the ongoing work and scientific publications showing main results.	Indicators: PI01#1 PI02#3 Target:
	Expected results: Development of medical devices for skin application as dressings for wound healing	Expected results description: Successful development of new prototypes of medical devices suitable for wound dressing, based on blends of collagen/gellan gum enriched with chitosan and other antimicrobial compounds, supporting protection and moisturizing towards wound repair.	
Action nr. 5	Action title: Marine ceramics for bone tissue therapies	Start date: 01-2018	End date: 12-2020
	Action description: The goal of this action is to develop medical devices based on marine ceramics that can be exploited for future use in bone tissue therapies. Two main strategies will be carried out. On one hand bioceramics having metallic nanoparticles will be produced for hyperthermia treatment of bone diseases. On the other hand, bioceramic nanoparticles will be obtained from fish bone to be combined with collagen in order to obtain nanocomposites for bone defect repair.		
Deliverables	Outputs title: Prototypes of bioceramics for hyperthermia treatments and bioceramic nanocomposites for bone defect repair. Reports and scientific publications about the results obtained.	Outputs description: Prototype of medical devices based on bioceramics containing metallic nanoparticles for hyperthermia treatments and based on bioceramic nanoparticles/collagen nanocomposites for bone repair. Periodic reports: ongoing work and scientific publications	Indicators: PI01#2 PI02#3 Target:
	Expected results: Development of medical devices for bone tissue therapies.	Expected results description: Successful development of new prototypes of medical devices suitable for bone tissue therapies based on hyperthermia and for bone repair based on bioceramic nanoparticles/collagen nanocomposites.	

WP Nr. 6	Activity	No	Duration in months	Activity start year and month	Activity end year and month	Activity budget
	Marine Ingredients for cosmetics, well-being and healthcare products		25	2018-06-01	2020-06-30	463,174.00€
Partners' involvement						
Partner responsible		5				
Partners involved		4,5,6,7,17				

The aim of this WP is to identify new marine compounds (from macro-algae, halophytes and cyanobacteria) with bioactivities of interest for SMEs in the fields of cosmetics, as YSLAB. Complementary expertise and technical resources of WP partners will be used to achieve the objectives defined in each action.

In particular, WP6 aims to deliver: i) New molecules with bone anabolic properties; ii) New compounds with antimicrobial and/or anti-biofilm activities for cosmetics, medical and healthcare markets; iii) Extracts with anti-obesity activity for well-being and health markets; iv) Nanoparticles-based systems to deliver marine hydrolysates for cosmetic applications.

The extracts, their fractions and derived purified compounds exhibiting the mentioned biological activities represent a new know-how acknowledged by enrolled research institutions and company and such improved competencies will strengthen their capacity to access public funds (namely Horizon 2020) and thus their role as innovation actors. Moreover, YSLAB will be capable to integrate the new know-how on its innovation chain (enhanced financing absorptive capacity), towards the development of new commercial products. This market-driven approach can be further supported by the higher leverage power associated to the solid scientific background of industrial processes. YSLAB represents a pilot action, replicable and transferable outside Atlantic Area regarding the consolidation of blue economy at European level.

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).				
Action nr. 1	Action title: Extracts from marine resources with bone anabolic properties		Start date: 06-2018	End date: 06-2020
	Action description: The aim is to produce purified extracts with bone anabolic properties and characterize their chemical structures. Extracts will be prepared from cyanobacteria and marine plants (macroalgae and halophytes) and tested for proliferative/mineralogenic/osteogenic activities using in vitro and in vivo fish systems. Synergistic effects will also be evaluated. Supplementation of scaffold with bioactive compounds to facilitate cell adhesion/proliferation will be tested in WP5.			
Deliverables	Outputs title: Extracts/fractions exhibiting pro-mineralogenic and/or osteogenic activities	Outputs description: Library with purified algae/halophytes extracts enriched in polyphenols (10) and fractionated extracts from cyanobacteria (315 fractions); Evaluation of bone anabolic activity of the extracts/fractions (alone/combined)	Indicators: PI01#1 PI02#3 OA1#1 CO41#1	Target:
	Expected results: List of polyphenols and active fractions with quantified biological activities	Expected results description: Polyphenols and active fractions isolated from macroalgae, halophytes and cyanobacteria characterized for cytotoxic, proliferative and mineralogenic activities using in vitro cell systems and for osteogenic activity using in vivo zebrafish systems		
Action nr. 2	Action title: Extracts from marine resources with anti-oxidant, antimicrobial and/or anti-biofilm activities		Start date: 06-2018	End date: 06-2020
	Action description: This action will focus on the assessment of the antioxidant, antibacterial and anti-biofilm activities of extracts and fractions obtained in A6.1, in order to replace existing additives with detrimental secondary effects. Their antibacterial activity and their capacity to prevent bacterial biofilm formation by inhibition of adhesion and/or quorum sensing will be tested on bacterial strains involved in infectious diseases or cosmetic spoilages. Cytotoxicity of extracts will be included.			
Deliverables	Outputs title: Polyphenol-rich extracts and cyanobacterial fractions exhibiting antioxidant, antimicrobial and/or anti-biofilm activities	Outputs description: Identification of new polyphenol-rich extracts and cyanobacterial pre-fractionated extracts with capacity to (i) prevent oxidation and to (ii) inhibit bacterial growth and biofilm formation	Indicators: PI01#1 PI02#2 OA1#1 CO41#1	Target:
	Expected results: Ranking of polyphenol-rich extracts/cyanobacterial fractions with quantified biological activities	Expected results description: Polyphenols or main components in cyanobacterial fractions characterized regarding antioxidant capacity, antibacterial and anti-biofilm activities on pathogenic and spoilage bacteria. Best candidates (excluding cytotoxic ones) will be selected/ranked		
Action nr. 3	Action title: Extracts from marine resources with anti-obesity activity		Start date: 06-2018	End date: 06-2020
	Action description: This action will focus on the analysis of extracts/fractions obtained in A6.1 for their beneficial activity towards obesity, and obesity-related co-morbidities (diabetes & fatty liver disease). The (i) anti-obesity activity will be analysed in zebrafish larvae by lipid staining, the (ii) anti-diabetes activity in zebrafish larvae and human liver cells by glucose bioprobes; and (iii) fatty liver disease in human liver cells by lipid staining. Cytotoxicity of extracts will be included.			
Deliverables	Outputs title: List of non-cytotoxic enriched extracts or fractions with quantified biological activities tackling obesity, diabetes, fatty liver disease	Outputs description: Enriched extracts and fractions characterized for activity towards (i) obesity, (ii) diabetes, and (iii) fatty liver disease. The most active fractions, without revealing cytotoxic behaviour, will be selected as leads for potential application.	Indicators: PI01#3 PI02#3 OA1#1 CO41#1	Target:
	Expected results: Characterization of enriched extracts or fractions with bioactivity for obesity or obesity-related co-morbidities	Expected results description: Enriched extracts and fractions will be characterized for their bioactivity towards (i) obesity, (ii) diabetes, and (iii) fatty-liver disease. Best candidates will be ranked by their potency, after excluding those with cytotoxicity.		
Action nr. 4	Action title: Nanocosmetics: particles for delivering collagen (gelatine) and hyaluronic acid hydrolysates from marine sources		Start date: 06-2018	End date: 03-2020
	Action description: The aim is produce nanoemulsions and nanosomes using marine origin compounds (IIM-CSIC, UBO) as vehicles to deliver bioactive ingredients (in particular collagen, hyaluronic acid hydrolysates and antioxidants from algae) for cosmetics. The functionality, physical properties, microbiological stability of nanoparticles using cell lines and in vivo, will be also tested. The potential incorporation of developed nanoparticulated systems in cosmetic formulations will be addressed (YSLAB).			
Deliverables	Outputs title: Cosmetic nanoparticles	Outputs description: Production of nanoemulsions and nanosomes using marine origin compounds isolated from fish by-products. Selection of optimal mixture of marine bioactive ingredients to be included in nanoparticles and assessment of delivery profile.	Indicators: PI01#2 PI02#2 OA1#1 CO42#1	Target:
	Expected results: New cosmetic ingredients	Expected results description: 1. Chemical characterisation of marine lipids from subproducts for nanoparticles 2. Optimal conditions for nanoparticle production 3. Optimal mixture of bioactive ingredients 4. In vitro evaluation of some healing activities		

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).

Please describe actions (max. 4) and deliverables within the Activity (the system must allow create a maximum of 4 actions).

6. BUDGET

6.1 Financing Plan by Partner

Partners	Programme Funding			Partner Contribution	External Contribution		Total Budget	Total Budget %	Part of Budget spent outside Programme Area		Other Fundings				Total Costs
	ERDF	Co-Financing Rate	ERDF %		Public Contribution	Private Contribution			Budget	% of Total	European Investment Bank	Revenues generated by the project	Others	Total	
Partner n.º 1 - Universidade do Minho	300114.00€	75%		100038	0	0	400,152.00€		28000	7.00%	0	0	0	0.00€	400,152.00€
									For scientific congresses, open access papers, and for the final capitalization event in Brussels						
Partner n.º 2 - Centro Tecnológico del Mar – Fundación CETMAR	103800.00€	75%		34600	0	0	138,400.00€		5200	3.76%	0	0	0	0.00€	138,400.00€
									For capitalization events at regional level (Spain) and the final event in Brussels, all outside PA						
Partner n.º 3 - Centro Interdisciplinar de Investigación Marinha e Ambiental	0.00€	75%		0	0	0	0.00€		0	1.43%	0	0	0	0.00€	0.00€
Partner n.º 4 - Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas	150000.00€	75%		50000	0	0	200,000.00€		2000	1.00%	0	0	0	0.00€	200,000.00€

Partners	Programme Funding			Partner Contribution	External Contribution		Total Budget	Total Budget %	Part of Budget spent outside Programme Area		Other Fundings				Total Costs
	ERDF	Co-Financing Rate	ERDF %		Public Contribution	Private Contribution			Budget	% of Total	European Investment Bank	Revenues generated by the project	Others	Total	
									For participating in one international congress and for one publication in an american journal						
Partner n.° 5 - Université de Bretagne Occidentale	226101.00€	75%		75367	0	0	301,468.00€		0	0.00%	0	0	0	0.00€	301,468.00€
Partner n.° 6 - SAS YSLAB	112500.00€	75%		37500	0	0	150,000.00€		10000	6.67%	0	0	0	0.00€	150,000.00€
									External expertise outside Programme area (Paris) will give biocompatibility data to the project.						
Partner n.° 7 - Universidade do Algarve	94341.00€	75%		31447	0	0	125,788.00€		0	0.00%	0	0	0	0.00€	125,788.00€
Partner n.° 8 - Universidad de Vigo	150537.00€	75%		50179	0	0	200,716.00€		10000	4.98%	0	0	0	0.00€	200,716.00€
									Project results will be presented in several International Conferences						

Partners	Programme Funding			Partner Contribution	External Contribution		Total Budget	Total Budget %	Part of Budget spent outside Programme Area		Other Fundings				Total Costs
	ERDF	Co-Financing Rate	ERDF %		Public Contribution	Private Contribution			Budget	% of Total	European Investment Bank	Revenues generated by the project	Others	Total	
									between 2017-2019.						
Partner n.º 9 - Royal College of Surgeons in Ireland	150000.00€	75%		50000	0	0	200,000.00€		0	0.00%	0	0	0	0.00€	200,000.00€
Partner n.º 10 - Universidade da Madeira	74976.00€	75%		24992	0	0	99,968.00€		0	0.00%	0	0	0	0.00€	99,968.00€
Partner n.º 11 - JELLAGEN PTY LTD	149850.00€	75%		49950	0	0	199,800.00€		0	0.00%	0	0	0	0.00€	199,800.00€
Partner n.º 12 - SURGACOLL Technologies Limited	190941.00€	75%		63647	0	0	254,588.00€		0	0.00%	0	0	0	0.00€	254,588.00€
Partner n.º 13 - Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal	84558.00€	75%		28186	0	0	112,744.00€		10430	9.25%	0	0	0	0.00€	112,744.00€
									Organization of the final event of capitalization outside Programme Area, in Brussels (Belgium).						
Partner n.º 14 - Axencia Galega de Innovación	0.00€	75%		0	0	0	0.00€		0		0	0	0	0.00€	0.00€
Partner n.º 15 - Agência Nacional de Inovação	0.00€	75%		0	0	0	0.00€		0		0	0	0	0.00€	0.00€
Partner n.º 16 - Agencia Estatal	0.00€	75%		0	0	0	0.00€		0		0	0	0	0.00€	0.00€

Partners	Programme Funding			Partner Contribution	External Contribution		Total Budget	Total Budget %	Part of Budget spent outside Programme Area		Other Fundings				Total Costs
	ERDF	Co-Financing Rate	ERDF %		Public Contribution	Private Contribution			Budget	% of Total	European Investment Bank	Revenues generated by the project	Others	Total	
de Investigación (MINECO)															
Partner n.º 17 - FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO	105183.00€	75%		35061	0	0	140,244.00€		2000	1.43%	0	0	0	0.00€	140,244.00€
									To participate in two international congresses.						
Total	1,892,901.00€	75.00%		630,967.00€	0.00€	0.00€	2,523,868.00€		67,630.00€	2.68%	0.00€	0.00€	0.00€	0.00€	2,523,868.00€

6.2 Budget explanation

6.2.1 Explain the budget preparation methodology (main assumptions and justifications)	Project leader set the rules for partners budgeting, assuming the main expenses in WP1 and quoting amounts for WP2/WP3. A budget limit was defined, based on the envisaged participation of each partner and assuring adequate distribution among regions. Benefiting from experience in previous AA projects, strictly necessary equipment and means were considered to succeed in the actions and deliver the results, relying on synergies and business approach to maximize efficiency of the use of resources.
6.2.2 Explain the partners involvement in the preparation of the budget	The Project leader defined the content of WP1 concerning meetings, audits, etc. CETMAR and AECT designed WP2 and WP3 with the agreement of all, with their commitment to get involved as strongly as to the other WPs, with active (time and financial) participation. Each partner, according to their skills and knowledge, defined the content of technical WPs from an innovative view and design the budget needed to accomplish those tasks with reasonable use of resources (best value for money approach).
6.2.3 If applicable, explain the investment budget (under budget lines: equipment/small infrastructures and works):	<p>FCUP: A rotavapor system (including chiller and pump) in the first year to be able to deal with the additional volume of extract preparation and fractionation</p> <p>SurgaColl: Purchase of a small dedicated freeze-dryer to achievement of the objectives in WP5</p> <p>UALG: Purchase a LED source of fluorescence (CoolLED). This piece of equipment is critical to the successful achievement of the objectives in action A6.1.</p> <p>CETMAR /AECT-GNP: Purchase of PCs to develop the WP2/3.</p> <p>All the equipment will be kept on the same institution, being used for the same purpose.</p> <p>All the other expenses indicated in this item are related with the acquisition of lab consumables, as plasticware and glass, reagents, solvents, standards, chromatographic columns, cell culture medium, cell lines, antibiotics, vacuum and lasers spare parts, ceramic crucibles, materials for fishing jellyfish, etc.</p> <p>It also contemplates the acquisition of small equipment like a vortex and a sonicator bath to process the extracts and fractions.</p>

6.2.4 Explain how the value for money will be ensured, i.e. how do you will reach the most advantageous combination of cost, quality and sustainability to meet project achievements?	A good coordination and a strict follow up of the timeframe and the results (internal monitoring and evaluation) are essential measures to minimize failures or deviations producing loss of efficacy of the available means for the project. Thus, all WP leaders will have a more detailed plan defining the tasks of each partner, together with a Risk Management Plan, re-assessed in each consortium meeting. Moreover, the partnership and strategy were built relying on synergistic efforts resulting from collaboration between partners, already established, allowing minimization of resources by removing redundancy costs. The results-oriented mind-set, given by the leadership of innovators (companies and entrepreneurial R+D centers), focuses the project to achieve effective transfer of knowledge to industry. A culture of close collaboration Companies/Research/Administration will be established, reinforcing the CVMar (4.9.1.) to cover territorial needs and enable sustainability of project results.
6.2.5 Complementary information	The partnership will execute an expenditure of 2.7% outside the Atlantic Area mainly as travels to attend Congresses. Inside the equipment an approximate expenditure of 5000 € is quoted for interpreting in communication and capitalization events. The budget guarantees the project profitability all the way long and it provides the means when necessary. There is a clear relationship between the amounts in the budget and the expected goals and products.

6.3 Budget Plan per Partner, Work Package and Year

Partners	Year														Total
	2017	%	2018	%	2019	%	2020	%	2021	%	2022	%	2023	%	
Partner n.º 1 - Universidade do Minho	0	0.00%	134690	33.66%	132190	33.03%	133272	33.31%	0	0.00%	0	0.00%	0	0.00%	400,152.00€
Partner n.º 2 - Centro Tecnológico del Mar – Fundación CETMAR	0	0.00%	55707	40.25%	42839	30.95%	39854	28.80%	0	0.00%	0	0.00%	0	0.00%	138,400.00€
Partner n.º 3 - Centro Interdisciplinar de Investigación Marinha e Ambiental	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 4 - Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas	0	0.00%	53650	26.82%	70438	35.22%	75912	37.96%	0	0.00%	0	0.00%	0	0.00%	200,000.00€
Partner n.º 5 - Université de Bretagne Occidentale	0	0.00%	106265	35.25%	121416	40.27%	73787	24.48%	0	0.00%	0	0.00%	0	0.00%	301,468.00€
Partner n.º 6 - SAS YSLAB	0	0.00%	58020	38.68%	76606	51.07%	15374	10.25%	0	0.00%	0	0.00%	0	0.00%	150,000.00€
Partner n.º 7 - Universidade do Algarve	0	0.00%	54318	43.18%	39773	31.62%	31697	25.20%	0	0.00%	0	0.00%	0	0.00%	125,788.00€
Partner n.º 8 - Universidad de Vigo	0	0.00%	69836	34.79%	69890	34.82%	60990	30.39%	0	0.00%	0	0.00%	0	0.00%	200,716.00€
Partner n.º 9 - Royal College of Surgeons in Ireland	0	0.00%	65425	32.71%	66550	33.27%	68025	34.01%	0	0.00%	0	0.00%	0	0.00%	200,000.00€
Partner n.º 10 - Universidade da Madeira	0	0.00%	19462	19.47%	50292	50.31%	30214	30.22%	0	0.00%	0	0.00%	0	0.00%	99,968.00€
Partner n.º 11 - JELLAGEN PTY LTD	0	0.00%	74475	37.27%	69200	34.63%	56125	28.09%	0	0.00%	0	0.00%	0	0.00%	199,800.00€

Partners	Year														Total
	2017	%	2018	%	2019	%	2020	%	2021	%	2022	%	2023	%	
Partner n.º 12 - SURGACOLL Technologies Limited	0	0.00%	98304	38.61%	80250	31.52%	76034	29.87%	0	0.00%	0	0.00%	0	0.00%	254,588.00€
Partner n.º 13 - Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal	0	0.00%	25698	22.79%	32038	28.42%	55008	48.79%	0	0.00%	0	0.00%	0	0.00%	112,744.00€
Partner n.º 14 - Axencia Galega de Innovación	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 15 - Agência Nacional de Inovação	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 16 - Agencia Estatal de Investigación (MINECO)	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 17 - FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO	0	0.00%	49484	35.28%	51685	36.85%	39075	27.86%	0	0.00%	0	0.00%	0	0.00%	140,244.00€
Total	0.00€	0.00%	865,334.00€	34.29%	903,167.00€	35.79%	755,367.00€	29.93%	0.00€	0.00%	0.00€	0.00%	0.00€	0.00%	2,523,868.00€

6.4 Line Budget plan by partner and budget line

Partners	Budget Line														Total
	PREPARION COSTS	STAFF FLAT RATE	STAFF	%	OFFICE AND ADMINISTRATIVE	%	TRAVEL AND ACCOMODATION	%	EXTERNAL EXPERTISE AND SERVICES	%	EQUIPMENT	%	SMALL INFRASTRUCTURE AND WORKS	%	
Partner n.º 1 - Universidade do Minho	0	0	237887	59.45%	35683.05	8.92%	21500	5.37%	29000	7.25%	76082	19.01%	0	0.00%	400,152.05€
Partner n.º 2 - Centro Tecnológico del Mar – Fundación CETMAR	0	0	73950	53.43%	11092.5	8.01%	12277	8.87%	33080	23.90%	8000	5.78%	0	0.00%	138,399.50€
Partner n.º 3 - Centro Interdisciplinar de Investigación Marinha e Ambiental	0	0	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 4 - Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas	0	0	120000	60.00%	18000	9.00%	12000	6.00%	6000	3.00%	44000	22.00%	0	0.00%	200,000.00€
Partner n.º 5 - Université de Bretagne Occidentale	0	0	182146	60.42%	27321.9	9.06%	19200	6.37%	10800	3.58%	62000	20.57%	0	0.00%	301,467.90€
Partner n.º 6 - SAS YSLAB	0	0	90000	60.00%	13500	9.00%	7200	4.80%	35000	23.33%	4300	2.87%	0	0.00%	150,000.00€
Partner n.º 7 - Universidade do Algarve	0	0	66815	53.12%	10022.25	7.97%	3600	2.86%	17600	13.99%	27751	22.06%	0	0.00%	125,788.25€
Partner n.º 8 - Universidad de Vigo	0	0	116188	57.89%	17428.2	8.68%	14600	7.27%	16500	8.22%	36000	17.94%	0	0.00%	200,716.20€

Partners	Budget Line														Total
	PREPARION COSTS	STAFF FLAT RATE	STAFF	%	OFFICE AND ADMINISTRATIVE	%	TRAVEL AND ACCOMODATION	%	EXTERNAL EXPERTISE AND SERVICES	%	EQUIPMENT	%	SMALL INFRASTRUCTURE AND WORKS	%	
Partner n.º 9 - Royal College of Surgeons in Ireland	0	0	121000	60.50%	18150	9.07%	16850	8.43%	8000	4.00%	36000	18.00%	0	0.00%	200,000.00€
Partner n.º 10 - Universidade da Madeira	0	0	49276	49.29%	7391.4	7.39%	6000	6.00%	1800	1.80%	35500	35.51%	0	0.00%	99,967.40€
Partner n.º 11 - JELLAGEN PTY LTD	0	0	120000	60.06%	18000	9.01%	19500	9.76%	19000	9.51%	23300	11.66%	0	0.00%	199,800.00€
Partner n.º 12 - SURGACOLL Technologies Limited	0	0	151474	59.50%	22721.1	8.92%	14256	5.60%	11137	4.37%	55000	21.60%	0	0.00%	254,588.10€
Partner n.º 13 - Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal	0	0	55612	49.33%	8341.8	7.40%	7095	6.29%	41695	36.98%	0	0.00%	0	0.00%	112,743.80€
Partner n.º 14 - Axencia Galega de Innovación	0	0	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 15 - Agência Nacional de Inovação	0	0	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 16 - Agencia Estatal de Investigación (MINECO)	0	0	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0.00€
Partner n.º 17 - FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO	0	0	79847	56.93%	11977.05	8.54%	4500	3.21%	12400	8.84%	31520	22.48%	0	0.00%	140,244.05€
Total	0.00€	1,464,195.00€	1,464,195.00€	58.01%	219,629.25€	8.70%	158,578.00€	6.28%	242,012.00€	9.59%	439,453.00€	0.00%	0.00€	0.00%	2,523,867.25€

6.5 Budget plan by partner and workpackage

Partners	Work Package																Total
	WP0-Project Preparation	%	WP1-Project Coordination	%	WP2-Communication	%	WP3-Capitalization	%		%		%		%		%	
Partner n.º 1 - Universidade do Minho	0	0.00%	53601	13.40%	25926	6.48%	16763	4.19%	143110	35.76%	160752	40.17%	0	0.00%			400,152.00€
Partner n.º 2 - Centro Tecnológico del Mar – Fundación CETMAR	0	0.00%	52485	37.92%	65437	47.28%	20478	14.80%	0	0.00%	0	0.00%					138,400.00€
Partner n.º 3 - Centro Interdisciplinar de Investigação Marinha e Ambiental	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %					0.00€
Partner n.º 4 - Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas	0	0.00%	28300	14.15%	4300	2.15%	2300	1.15%	58400	29.20%	53800	26.90%	52900	26.45%			200,000.00€

Partners	Work Package																Total
	WP0-Project Preparation	%	WP1-Project Coordination	%	WP2-Communication	%	WP3-Capitalization	%		%		%		%		%	
Partner n.º 5 - Université de Bretagne Occidentale	0	0.00%	31975	10.61%	8325	2.76%	10450	3.47%	91174	30.24%	0	0.00%	159544	52.92%			301,468.00€
Partner n.º 6 - SAS YSLAB	0	0.00%	11890	7.93%	6422	4.28%	1788	1.19%	44934	29.96%	0	0.00%	84966	56.64%			150,000.00€
Partner n.º 7 - Universidade do Algarve	0	0.00%	6010	4.78%	31157	24.77%	22398	17.81%	0	0.00%	0	0.00%	66223	52.65%			125,788.00€
Partner n.º 8 - Universidad de Vigo	0	0.00%	13801	6.88%	5715	2.85%	13450	6.70%	0	0.00%	167750	83.58%	0	0.00%			200,716.00€
Partner n.º 9 - Royal College of Surgeons in Ireland	0	0.00%	29100	14.55%	3450	1.73%	17295	8.65%	52705	26.35%	97450	48.73%	0	0.00%			200,000.00€
Partner n.º 10 - Universidade da Madeira	0	0.00%	11889	11.89%	7112	7.11%	5334	5.34%	75633	75.66%	0	0.00%	0	0.00%			99,968.00€
Partner n.º 11 - JELLAGEN PTY LTD	0	0.00%	22000	11.01%	4950	2.48%	9900	4.95%	162950	81.56%	0	0.00%	0	0.00%			199,800.00€
Partner n.º 12 - SURGACOLL Technologies Limited	0	0.00%	21200	8.33%	12075	4.74%	9990	3.92%	0	0.00%	211323	83.01%	0	0.00%			254,588.00€
Partner n.º 13 - Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal	0	0.00%	26399	23.41%	8547	7.58%	77798	69.00%	0	0.00%	0	0.00%	0	0.00%			112,744.00€
Partner n.º 14 - Axencia Galega de Innovación	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %			0.00€
Partner n.º 15 - Agência Nacional de Inovação	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %			0.00€
Partner n.º 16 - Agencia Estatal de Investigación (MINECO)	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %	0	NaN %			0.00€
Partner n.º 17 - FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO	0	0.00%	23967	17.09%	6368	4.54%	10368	7.39%	0	0.00%	0	0.00%	99541	70.98%			140,244.00€
Total	0.00€	0.00%	332,617.00€	13.18%	189,784.00€	7.52%	218,312.00€	8.65%	628,906.00€	24.92%	691,075.00€	27.38%	463,174.00€	18.35%			2,523,868.00€

6.6 Complementary information

6.6.1 In Kind Contribution			
Partners	Budget	% of Total Budget	Explanation
Partner n.º 1 - Universidade do Minho			
Partner n.º 2 - Centro Tecnológico del Mar – Fundación CETMAR			
Partner n.º 3 - Centro Interdisciplinar de Investigación Marinha e Ambiental			
Partner n.º 4 - Instituto de Investigaciones Marinas - Consejo Superior de Investigaciones Científicas			

6.6.1 In Kind Contribution			
Partners	Budget	% of Total Budget	Explanation
Partner n.º 5 - Université de Bretagne Occidentale			
Partner n.º 6 - SAS YSLAB			
Partner n.º 7 - Universidade do Algarve			
Partner n.º 8 - Universidad de Vigo			
Partner n.º 9 - Royal College of Surgeons in Ireland			
Partner n.º 10 - Universidade da Madeira			
Partner n.º 11 - JELLAGEN PTY LTD			
Partner n.º 12 - SURGACOLL Technologies Limited			
Partner n.º 13 - Agrupación Europea de Cooperación Territorial Galicia Norte de Portugal			
Partner n.º 14 - Axencia Galega de Innovación			
Partner n.º 15 - Agência Nacional de Inovação			
Partner n.º 16 - Agencia Estatal de Investigación (MINECO)			
Partner n.º 17 - FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DO PORTO			

6.6.2 Physical Investment						
ID	Name of the organization	Investment Title	Investment Budget	Technical Description and justification	Investment requirements	Ownership and durability

Output Indicators

Outputs	Work Package
	Target value
Number of enterprises participating in cross-border, transnational or interregional research projects (common indicator N° 41)	9
Number of research institutions participating in cross-border, transnational or interregional research projects	9
Project reports	22
Internal project meetings and events	26
Number of case studies and pilot actions implemented	25
Number of policy, strategy and operational instruments produced	6
Project newsletters and other information documents	9
Number of actions for the dissemination and capitalisation of results	21
Number of participants in actions for the dissemination and capitalisation of results	130
Number of technical and scientific publications produced	32

Reports Delivering Chronogram

Year	Reports	With payment claim / Without payment claim	Date expected to be deliver	Total amount expected to be claim
2018	1º Half Report	With payment claim	2018-07-01	302,864.16
2019	1º Half Report	With payment claim	2019-01-01	328,102.84
2019	2º Half Report	With payment claim	2019-07-01	378,580.20
2020	1º Half Report	With payment claim	2020-01-01	630,967.05
2020	2º Half Report	With payment claim	2020-07-01	630,967.05
2021	1º Half Report	With payment claim	2021-01-01	252,386.80